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Abstract
Currently, the primary biomarker for radiation biodosimetry is the dicentric chromosome.
However, the γ-H2AX histone is an alternative assay that is less labour-intensive. Blood
samples can be taken more quickly than for the dicentric biomarker, and a larger number
of samples can be handled within a given time frame. In this thesis, we discuss sev-
eral statistical techniques for how to handle scored γ-H2AX foci data. We then apply
these techniques to two datasets from Public Health England, using one to demonstrate
techniques, and the second to check that the dose-response curve calculation and dose
estimation techniques work. Throughout we choose to fit quasi-Poisson models instead
of Poisson ones to account for overdispersion present within the foci count data. After
fitting both linear and quadratic dose-response curves we create controls to validate the
curves, using a reference sampling ratio to scale them if necessary. By calculating the un-
certainty we show why linear fits are preferable to quadratic ones. We finally compare our
linear dose-response curves from both datasets for multiple timepoints with pre-existing
ones from the literature to see how they compare and what conclusions can be drawn about
dose-response curves for this assay in general.
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Chapter 1
Introduction
In this day and age, the use of nuclear power and radioactive materials means that there is
a risk to the public of accidental irradiation, should something go wrong. In a radiation
incident, scientists need to be able to rapidly and reliably determine each individual
victim’s level of exposure and thus the dose that they have contracted. However, we have
an issue, namely that we cannot guarantee that an exposed individual will be wearing
a radiation dosimeter (members of the public typically do not) [1]. According to their
review, 37% (27) of the cases investigated by Public Health England (PHE) between 2006
and 2015 were listed as “Suspected overexposure of people not wearing a dosimeter” [2].
The majority (59%, or 43 cases) of the 73 investigations during that decade were due to
possible non-uniform exposure, specifically “that in which the relationship between dose
to the physical dosimeter and to the body is uncertain”. This sort of situation is one
where an unexpectedly high dosimeter reading is recorded, and samples are taken as a
precaution.
Biological dosimetry is useful because it can be used to initially split victims into two
groups: those deemed to be “critically exposed”, who should be prioritised, and the “wor-
ried well”, people who have (comparatively) been minimally exposed thus are unlikely
to need urgent treatment [3]. As well as this, it can provide us with useful information
regarding the probable future health consequences, both stochastic and deterministic, for
victims of radiation incidents [4].
1.1 Radiation Dose Modelling
The most commonly used type of biomarker is chromosomal aberrations, wrapped-up
DNA that has been damaged or otherwise altered by ionising radiation.
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1.2 The Dicentric Biomarker
Currently, the main aberration used in biological dosimetry is the dicentric chromosome.
This is a chromosome with two centromeres (“crossings”) instead of the usual one. It is
formed by an exchange between the centromeric pieces of two broken chromosomes, and
in the complete form the resultant dicentric chromosome is accompanied by an acentric
fragment which is composed of the remaining pieces of the broken chromosomes and does
not contain a centromere [5].
The dicentric chromosome is a cytogenetic biomarker, a type of biomarker that counts
chromosomal aberrations in blood lymphocytes. Cytogenetic biomarkers have been con-
sidered to be the “gold standard” for radiation biodosimetry for three decades, mostly
due to a comparative lack of inter-individual variation [6].
Due to the amount of research that’s been done into it and the widespread utilisation
of this method, the dicentric chromosome should be considered to be a “best possible”
albeit imperfect choice of biomarker, as it has a few primary limitations. Firstly, reli-
able samples cannot be taken immediately after exposure as it takes at least 2 days to
obtain suitable metaphase spreads following irradiation and subsequent stimulation of
lymphocytes [7]. The analysis itself is both time-consuming and requires experienced cy-
togeneticists in order to produce an accurate assessment of the level of radiation damage.
As a result, the total number of cases that can be assessed globally in any given week is
approximately 3000 [7]. This figure is as high as it is due to well developed international
mutual assistance networks such as the EU funded project RENEB (Realising the Euro-
pean NEtwork of Biodosimetry) [8]. This presents us with a clear issue: should there be
a large-scale radiation incident, triage of casualties may well be dangerously slow, poten-
tially posing long-term harm to victims’ health. Therefore, other biomarkers should be
investigated that can be assessed sooner and more quickly.
1.3 The Public Health England Factsheet
In this project we will analyse an unpublished internal factsheet (2.5 pages) from Public
Health England [9] entitled “Dose and uncertainty estimation with the gamma-H2AX
assay”. This factsheet briefly and succinctly discusses suggested procedures to estimate
doses from blood or lymphocyte samples using the γ-H2AX assay biomarker. We will
discuss and explore the techniques detailed on it with reference to the field of biodosimetry
as a whole then apply them to two PHE datasets. The first dataset, henceforth referred
to as PHE (2017), is our primary dataset, as it contains a greater number of design doses
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for each time point (as well as a larger number of usable measurements) and was fully
available when this thesis was started. The second dataset is known as PHE (2018) and is
used to check that the methods described work for scenarios other than the first dataset.
Some of the material in this thesis fed into a paper that has been accepted for pub-
lication. (The author of this thesis is listed as a co-author of the paper.) This paper,
entitled “A statistical framework for radiation dose estimation with uncertainty quantifi-
cation from the γ-H2AX assay”, has been published by the journal PLoS One, and any
figures used from it will be suitably cited [10]. The aim of the paper is to establish a
combined statistical methodology for calibration curve estimation, dose estimation, and
uncertainty quantification for the γ-H2AX assay, as currently practical use of the assay
is limited by a lack of agreement on which strategies to use. This contrasts with the
dicentric assay, which has standardised procedures, as given in the IAEA manual (2011)
[5].
1.4 Introducing the First Dataset
Our initial dataset contains 339 foci/cell measurements (also known as “yields”). 32
individual PHE staff volunteers provided blood samples, which were then irradiated ex-
vivo with 250 kVp X-rays. For this dataset 7 design dose points were used: 0Gy, 0.05Gy,
0.1Gy, 0.25Gy, 0.5Gy, 1Gy, and 4Gy. Yields were recorded at only two time points after
exposure, 1h and 24h, for groups of n = 500 cells.
Figure 1.1 is an initial scatterplot of the raw data, colour coded by timepoint. Here
we have that the spread of data increases with dose, and that the 24h data has a smaller
spread than the 1h data at every dose marker where comparison is possible. Excluding
one potential (large) outlier, the 4Gy 24h data has a smaller spread than the 1Gy 1h data.
There are clear positive trends within the data, although it is clear that the foci/cell count
is higher overall and increases at a larger rate for the 1h data.
The number of measurements used per individual varies from 1 (person H62) to 32
(person H9), as shown in Figure 1.2. All of the models we fitted utilised data from multiple
samples, choosing not to consider the sampling individual. This implies an assumption
of inter-individual variation between foci counts that is not larger than intra-individual
variation, something that is taken to be standard with regards to this area of biodosimetry
and will be discussed further in Chapter 2. That being said, should an individual’s sample
results later be found to be compromised for some reason the label can be used to suitably
remove those readings only from the dataset. Labelling the individuals (anonymously)
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Figure 1.1: A scatterplot showing the raw data from the PHE (2017) dataset, colour
coded by timepoint. The 1h data is shown in black, whilst the 24h data is shown in red.
also allows us to double check levels of inter-individual variation if we choose to do so,
although we must be mindful of the wildly varying number of samples per person.
Of the 339 measurements in this dataset, 78 of them (just over 23% of the total) were
control measurements, those taken at a dose point of 0Gy. Aside from those, the most
common dose for samples to be exposed to was 0.5Gy (74 measurements, or approximately
21.8%). The three lowest exposed doses (0.05Gy, 0.1Gy, and 0.25Gy) tied with the least
numbers of measurements at 32 each. For the highest three doses (0.5Gy, 1Gy, 4Gy) used
in this dataset the number of readings decreases with dose by 19 each time (74, 55, 36).
It must be noted, however, that the 4Gy data is all from a single timepoint (24h), whilst
every other dose records at least one measurement from each of the two timepoints.
Figure 1.3 shows the number of readings per design dose for each timepoint, and it
should be noted that the only dose where we have more 24h measurements than 1h ones is
4Gy, where we have no data for the 1h timepoint. We have equal numbers of readings per
timepoint (16 per timepoint per dose) for three out of the seven stated doses (0.05Gy,
0.1Gy, 0.25Gy). It is noticeable that these are the three lowest doses that cells were
irradiated with, and that (excluding the 0 recorded for the 1Gy and 4h combination) this
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Figure 1.2: A bar chart showing the number of measurements (foci counts per 500 cells)
taken per individual, sorted in order of anonymous user code. From [10].
number of measurements recorded for each dose and time pair is the joint lowest. This
could potentially be due to difficulties working with very small doses. For the 1Gy data
we almost have an equal number of readings per timepoint, with 28 for 1h and 27 for
24h. This suggests that there may have initially been an equal number of readings taken
per timepoint, although if so clearly at least one was unusable. For the other two doses
where we have readings for both timepoints (0Gy and 0.5Gy) we have over twice as many
readings for the 1h data than for the 24h data. Of the 78 control measurements, only 22
of them were taken 24h after exposure. Nearly three-quarters of the 74 readings taken
at 0.5Gy were taken 1h after exposure (55 were taken after 1h, the other 19 after 24h).
The dose with the largest number of 24h readings is 4Gy, which has 36 of them.
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Figure 1.3: A bar chart showing the number of measurements recorded for each of the
seven doses in the dataset, sorted by timepoint.
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Chapter 2
The γ-H2AX Histone Biomarker
In this thesis we will focus on the γ-H2AX biomarker.
Figure 2.1: A trio of cells (blue) containing γ-H2AX foci (green), that have been stained
using immunofluorescence microscopy. The two white arrows show the heterogeneity of
foci sizes found in a single cell. The red arrow shows a group of foci close together that
may easily be incorrectly scored as a single large focus, an example of a common scoring
error [11].
2.1 Biological Background
Chromosomes in an organism are made of a substance called chromatin, which itself
consists of nucleosomes in more complex, higher order structures [13]. These nucleosomes
are composed of both DNA and octamers of histones, groups of eight proteins that are
10
Figure 2.2: A set of four images showing the effect of increased dose on the generation
of γ-H2AX foci. All samples were scored the same amount of time after irradiation. It is
clear that the greater the amount of radiation exposed to, the greater the number of foci
generated [12].
used to package the DNA double helix. Specifically, DNA is wrapped around the eight
protein structure. Each octamer is made from four types of histone, H2A, H2B, H3, and
H4, and each type of histone is represented twice [14]. The H2A histone has four subtypes,
which are grouped into three subfamilies: H2A1-H2A2, H2AZ, and H2AX [13]. We are
focussing on H2AX, which can account for anything from 2% to 20% of the H2A histones
found in human cells. Our data refers specifically to lymphocytes, which typically only
contain 2% H2AX [15].
The H2AX subtype has a specific role, namely that it is able to repair double strand
breaks (DSBs) in DNA following a nucleosome’s exposure to low doses of ionising ra-
diation [14]. When said DSBs occur, the H2AX histone phosphorylates, a process that
results in the formation of γ-H2AX foci, which can be observed as fluorescent dots [6].
The background rate of γ-H2AX foci is very low (0.1 per cell or less in unirradiated
peripheral blood mononuclear cells and normal human fibroblasts in stationary phase)
[15]. The phosphorylation is only visible for up to approximately 24 hours after radiation
exposure [6]. DSBs are spontaneously induced at a very low rate, and very few other
biologically relevant processes induce them, so the presence of a significant amount of
DSBs implies that an organism has been exposed to ionising radiation [15].
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2.2 Foci Scoring
Although the initial research on this biomarker was done using animal tissue samples,
primarily mouse livers [13], this is massively impractical when dealing with irradiated
humans, so blood samples are used instead.
According to Rothkamm & Horn in 2009, γ-H2AX analysis should take place between
30 minutes and 1 hour after a full body exposure, as at this point the vast majority of
the induced foci are both present and at a size and intensity where they can be scored
reliably [15]. However, this is unrealistic when considering a radiation incident, especially
a triage situation with a large number of potential casualties. Therefore, samples should
be taken as soon as possible, ideally within 24 hours, with a potential upper limit for
feasibility of approximately 3 days [16].
These blood samples are then scored, either manually in a process called immunoflu-
orescence microscopy, or automatically through flow cytometry using machinery such as
MetaCyte [17]. However, automated scoring can have consistency issues [18], so the data
we are looking at has been manually scored. The main control issues to consider when
scoring samples are the point at which dim foci are classified as background noise, due to
their low intensity or small size, and the potential for groups of foci in close proximity to
each other that can easily be perceived as fewer in number than they actually are. Both
of these may be affected by differences in the optical resolution and light efficiency of the
microscope and camera used for the imaging of the foci [15], as well as the discretion of
the individual scorer. Indeed, this is an issue we later came across when analysing the
newer of our two datasets: there were two researchers scoring the data, and one recorded
consistently higher foci counts than the other. This can be accounted for by including
mathematical methods to “normalise” the data and thus allow for comparison across a
full dataset.
2.3 Comparison with Dicentric Biomarker
When comparing the γ-H2AX histone biomarker with its dicentric counterpart, we must
first be aware that they are two different types of biomarker. The dicentric biomarker is a
cytogenetic biomarker, one that counts chromosomal aberrations in blood lymphocytes,
whilst the γ-H2AX histone is a protein-based biomarker that relies on the phosphory-
lation of proteins for analysis [6]. The dicentric biomarker is very well established in
the literature, with clear and comprehensive statistical methods, whilst the γ-H2AX hi-
stone is not (the aim of our aforementioned paper [10] is to establish a unified statistical
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methodology for this biomarker). A key strength of the dicentric biomarker is that it has
very little inter-individual variation. This is not true for the γ-H2AX biomarker, which
has, as well as potential inter-individual variation, far stronger inter-laboratory varia-
tion [14]. However, the time required between sampling and analysis is far shorter for
γ-H2AX foci (a few hours) than for the dicentric biomarker (2-3 days) [18]. The dicentric
biomarker also has a lower throughput than the γ-H2AX histone and is more labour
intensive, requiring experienced and skilled cytogeneticists. As a result of this the global
weekly capacity for analysis of the dicentric biomarker in “triage mode” (scoring only 50
cells per sample and with a detection limit of 0.5Gy) is approximately 3000 samples [7],
clearly not practical for a situation with a high number of potential casualties. There
is no currently stated upper limit for the number of γ-H2AX histone samples scored
per week, but it is reasonable to assume that any such limit would be far larger than
3000. The γ-H2AX histone biomarker operates within comparatively strict time limits:
the phosphorylated foci initially form within minutes of exposure [18], but are typically
only visible until approximately 24 hours after [6]. In comparison, while a blood sample
can be taken within a few hours of a whole body exposure for the dicentric biomarker,
delaying taking a sample until over 24h later is “advisable” if a non-uniform or partial
body exposure is suspected [5]. Otherwise, IAEA guidelines suggest that blood samples
for analysis of this biomarker be obtained “promptly” but give no strict upper limit,
suggesting that aberration yields will drop after four weeks, increasing uncertainty [5].
13
Chapter 3
Constructing Dose-Response
Calibration Curves
The process of dose estimation can be broken down into two steps. Firstly, a dose-
response curve is fitted, which may be either linear or quadratic. The equation for this
dose-response curve comes from fitting a generalised linear model (GLM) to the chosen
subset of calibration data. Data is typically subsetted by time of exposure. In this
chapter we will discuss the underlying statistical techniques and methodology utilised
when fitting these models and thus the resulting calibration curves. The dose estimation
process and the subsequent estimation of uncertainty will be discussed in Chapter 4.
3.1 Exponential Family
The exponential dispersion family (EDF) of probability distributions can be written in
the following form:
P (z|θ, φ) = exp
[
zθ − b(θ)
φ
+ c(z, θ)
]
(3.1)
where:
• θ ∈ R is the so-called ‘natural parameter’;
• φ > 0 is the ‘dispersion parameter’, the one that we are focussing on here;
• b : R→ R and c : R× R>0 → R are both functions. We know that
η = b′(θ) (3.2)
is the linear predictor (see Section 3.2) and slope parameter, and
V(η) = b′′(θ) (3.3)
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is the variance function of η.
The Poisson distribution is an EDF with z ∈ N. It can be expressed as
P (z) =
e−λλz
z!
= exp [z lnλ− λ− ln z!] (3.4)
for integer z [19].
In this case we have that
• θ = lnλ;
• φ = 1;
• b(θ) = eθ = λ;
• c(z, φ) = − ln z!.
3.1.1 Dispersion
The dispersion parameter φ is a parameter of the exponential family that denotes the
ratio of the variance to the mean. In the Poisson case it can be calculated by dividing
the variance by the mean. As the Poisson model has equidispersion, the value of φ
for a Poisson fit is always 1. Therefore one can think of φ as the dispersion relative
to the Poisson dispersion. If φ > 1 we have overdispersion, whilst φ < 1 represents
(hypothetical) underdispersion.
Overall, the dispersion parameter exists to account for “extra variation” within data
and is often referred to as a “nuisance” parameter, but is actually of critical importance
when constructing a quasi-Linear model of any type. The size of the dispersion parameter
does not affect the value of the mean, but it does affect the spread of the data, acting to
scale the variance and thus the standard error.
3.2 Generalised Linear Models
Generalised Linear Models (GLMs) are a class of models that generalise linear regression
where the response variable is expected to follow an EDF distribution with mean µ. They
are specified by three components, namely:
• η = ωTx, the linear predictor [20], where ω is a p-dimensional vector of unknown pa-
rameters and x is a p-dimensional design vector of predictors that is an appropriate
function of the actual covariates;
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• h, an injective response function. We have that
µ = E[z|x] = h(η) = h(ωTx).
Its inverse g = h−1, also written as
g(µ) = η = ωTx,
is the link function. This and the linear predictor form the structural assumption;
• The type of the exponential family that categorises the response function, which
is the distributional assumption. In a GLM our knowledge of z given x and ω is
described by an EDF whose parameters depend on x and ω:
P (z|x, ω) = P (z|θ(x, ω), φ) = exp
(
zθ − b(θ)
φ
+ c(z, θ)
)
.
The responses Z are conditionally independent given x. Therefore:
P ({zi}|{xi}) =
∏
i
P (zi|xi, ω) (3.5)
3.2.1 Poisson Models
Typically a Poisson distribution is used to model cytogenetic biodosimetry data [5]. The
Poisson distribution is a count based statistical distribution with probability density
function P (z) = e
−λλz
z!
(see Equation 3.4). The single parameter λ is the mean number
of times an event occurs in an interval. The Poisson distribution is notable in that both
the expectation and the variance are also λ. The equality of the mean and the variance
in particular is known as equidispersion [20]. However, real life data frequently violates
equidispersion. With biomarker data the type of violation that we are most likely to
encounter is overdispersion, where the variance exceeds the mean. (Underdispersion,
where the mean exceeds the variance, can occur but is typically far rarer.)
For the aforementioned dicentric biomarker, a Poisson distribution has been shown to
be sufficient for a homogeneously irradiated population of blood lymphocytes by Hilali et
al in 1991 [21]. As the data we are using includes lymphocytes that have been irradiated
in laboratory conditions, we assume homogeneity of irradiation. Thus, we are testing
initially how well the Poisson distribution fits this γ-H2AX data, to see if the goodness
of fit is dicentric biomarker specific or not, an assumption that has been made previously
[22]. We are then utilising a second fitting model as a comparison, specifically the quasi-
Poisson model, which will be discussed in Section 3.2.5.
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Throughout this thesis, we will only be using data from whole body irradiation scenar-
ios, i.e. ones where we assume that the entire body has been irradiated an equal amount.
This is done for ease of modelling and calculation. Partial body models do exist, and
they will be briefly discussed in Chapter 6.
Another issue to consider is the potential for zero inflation, which occurs when the
number of zeros in a sample significantly exceeds the expected amount. This is commonly
observed with count data, where the number of zeros generated by a Poisson distribution
is less than the number observed [23], and is a phenomenon closely related to overdisper-
sion. Again, this issue and potential solutions to it will be discussed further in Chapter
6.
When fitting a generalised linear model in R, a link function must be stated. The link
function is a response function that relates the linear predictor to the mean function of the
chosen exponential family distribution. Typically the preferred link to use statistically
is the canonical link function, one that is derived from the exponential of the density
function. For the Poisson distribution this is the log link g(µ) = exp(ωTx). For this
biomarker data, however, we have chosen to deviate from the canonical link for biological
reasons, instead using the identity link g(µ) = ωTx, as this relationship has both been
empirically observed [24] and can be physically justified [15]. This guarantee is needed
for feasibility, as the mean/expected Poisson count can never go below 0 for count data.
The identity link gives a fitted model of the form µ =
∑
i θiD
i for a vector of coeffi-
cients θ and powers of the dose, D, from which fitting equations can be constructed. We
chose to use the coefficients A,α, and β and set y = µ = E(z), to give
y = A+ αD (3.6)
and
y = A+ αD + βD2 (3.7)
These equations will later be used for dose estimation with a known yield y.
3.2.2 The Score Function (General Case)
A maximum likelihood estimate (MLE) with log-likelihood L satisfies the score equation
S(ωˆ) = ∂L
∂ωT
(ωˆ) = 0, which comes from the score function S(ω) = ∂L
∂ωT
.
In the general form we have
S(ω) =
∂L
∂ωT
=
∑
i
∂Li
∂ωT
=
∑
i
∂Li
∂θi
∂θi
∂µi
∂µi
∂ηi
∂ηi
∂ωT
,
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with
∂Li
∂θi
=
zi − b′(θi)
φ
=
zi − µi
φ
.
Using Equations 3.2 and 3.3, we know that:
∂θi
∂µi
=
∂(b′)−1
∂µi
=
1
b′′((b′)−1(µi)
=
1
b′′(θi)
=
1
V(µi)
∂µi
∂ηi
= h′(ηi)
∂ηi
∂ωT
= xi
3.2.3 The Score Function (Poisson Case)
For this dataset, the initial type of model that we are fitting is the Poisson model with
identity link λ(x) = µ(x) = ωTx. The likelihood function is given by
L = exp
(∑
i
(−µi) + zi ln(µi)− ln(zi!)
)
= exp
(∑
i
(−ωTxi) + zi ln(ωTxi)− ln(zi!)
)
We have that
∂Li
∂θi
= zi − µi = zi − ωTxi
∂θi
∂µi
=
1
µi
=
1
ωTxi
∂µi
∂ηi
= 1
∂ηi
∂ωT
= xi
ηi is explicitly linked to the shape of the constructed curve, as it is calculated using the
curve coefficients.
Therefore in this scenario, the full score equation can be written as
S(ω) =
∑
i
(zi − µi) 1
µi
xi
=
∑
i
(
zi − ωTxi
) 1
ωTxi
xi
=
∑
i
(
zi
ωTxi
− 1
)
xi
Here we have that φ = 1 (as this is a Poisson model).
S(ω) =
∑
i
(
zi
ωTxi
− 1
)
xi
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3.2.4 Removing the Dispersion
S(ω) =
∑
i
(
zi − µi
φ
)(
1
V(µi)
)
h′(ηi)xi
S(ω) =
1
φ
∑
i
(zi − µi) 1V(µi)h
′(ηi)xi
The MLE ωˆ must satisfy S(ωˆ) = 0. However, the dispersion parameter φ cancels from
the score equation. This implies that ωˆ does not depend on φ.
3.2.5 Quasi-Poisson Models
As the value of ωˆ does not depend on φ, we can construct a so-called “quasi-Poisson”
model that utilises the majority of Poisson assumptions but allows for dispersion values
other than 1.
In general, quasi-likelihood models drop the exponential family assumption of likeli-
hood models. They also separate the mean and variance structure of the model, which is
especially relevant in the Poisson case when the equidispersion assumption is also being
removed.
Fitting a GLM using a quasi-Poisson model gives the same estimate values for coef-
ficients as a Poisson fit, and thus the values of the residuals are the same. The null and
residual deviance values are also the same. Obviously, the dispersion values differ between
Poisson and quasi-Poisson fits with the same link for identical data, but so too do the
standard errors on the coefficients. Quasi-Poisson models may not have distributional
forms; they are only characterised by mean and variance. Thus they do not have Akaike
information criteria (AIC) values. In 2002 Burnham and Anderson developed quasi-AIC,
but they only used it to compare various quasi-linear models instead of comparing quasi
class models to those with a distributional form (i.e. comparing quasi-Poisson to Poisson)
[25].
A quasi-Poisson model is preferable to a Poisson one for our γ-H2AX data due to the
amount of overdispersion present. In the examples below (Section 3.4), it can clearly be
seen that the dispersion parameter for our PHE (2017) data has a value of approximately
60. This indicates a large difference in size between the mean and variance values (the
variances are about 60 times larger than the means), and consequently a significant
violation of the Poisson model’s equidispersion principle.
19
3.3 Variability
3.3.1 Moments
For a GLM, the mean and variance structure are correctly specified by
E(z|x) = µ = h(ωTx),
Var(z|x) = σ2(µ) = φV(µ),
where V(µ) is a variance function [26]. It holds that the “updated” variance for the quasi-
Poisson fit can be calculated using the quasi-Poisson dispersion: that is, for parameter
estimates θˆ,
VarQ(θˆ) = φVarP (θˆ). (3.8)
3.3.2 Standard Error
The standard error on a measurement is the square root of the variance. Thus it follows
that when moving from a Poisson model to a quasi-Poisson one we multiply the Poisson
standard error SEP by the square root of the dispersion φ. Therefore, for parameter
estimates θˆ, we have that:
SEQ(θˆ) =
√
φSEP (θˆ) (3.9)
3.4 Examples
3.4.1 Checking Fit Type
A quick and easy way to test for equidispersion is to simply plot the means and variances
of the yields against each other, with a aggregated data point for each dose. Should
we have equidispersion, the resulting line of best fit will be a straight line of the form
x = y with the same scale on both axes. We do this in Figure 3.1, and it is immediately
obvious that we have overdispersion instead of equidispersion. For starters, the means and
variances are not even plotted on the same scale, with the means’ scale in the thousands
and the variances’ scale in the hundreds of thousands. The variances are shown to be
roughly 60 times larger than the means, suggesting that a fitted quasi-Poisson GLM
would have an estimated dispersion of φ ≈ 60.
If we were to introduce a line of best fit here, it would clearly be nothing near x = y,
and the 24h data may even be best served by fitting a curve to deal with the extremely
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large value outlier on the right hand side, should it not be an outlier, although further
measurements would be needed to clarify either way.
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Figure 3.1: A plot showing the relationship between the means and variances of the cells
in the PHE (2017) dataset. Clear differences in scale are visible, as is an obvious lack of
equidispersion. From [10].
3.4.2 Model Fitting & Calibration Curves
We have a large number of data points, so we chose to fit the time points separately
from each other. Initially we fitted eight different models, four Poisson and four quasi-
Poisson. However, the coefficients are mathematically identical, as discussed in Section
3.2.5, thus Table 3.1 records the quasi-Poisson (rounded) coefficients, along with the
dispersion values of each fit. Standard error values have been recorded separately in
Table 3.2 for later discussion/analysis. These four fits have been plotted in Figure 3.2
(and colour coded appropriately) on a graph of dose against foci/cell. For quadratic fits,
we expected to have that β < 0 due to the saturation effect, and indeed this is what we
found.
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All four of our final fits have similar intercept values of between 0.11 and 0.18, sug-
gesting that a so-called “true” background rate lies between those values. In both the
linear and the quadratic cases, the slope value decreases with time, whilst the intercept
increases slightly (by about 0.03 each time), although the latter observation may not
actually be notable. There is a large difference between 1h and 24h, time wise (especially
compared to a gap between time points like 1h and 4h), so the large decrease (by over 10
each time) in the slope value is understandable. Both of the β coefficients are negative,
as expected, with the 1h quadratic fit having a much larger curve than the 24h one. The
24h model has a very small negative curve coefficient, at only -0.094352. In fact, both
quadratic fits are very close to the linear ones, according to Figure 3.2. Therefore it
is especially worth looking at the uncertainty values in this case to determine whether
or not the amount of uncertainty introduced by each quadratic (or β) term justifies its
inclusion. It remains to be seen whether the relative sizes of the β terms appear to be
“typical” for their time points, although there is a dearth of fit values to compare in this
case, as linear fits are typically preferred for γ-H2AX data.
From our initial plot of means against variances, we estimated that any fitted quasi-
Poisson GLMs from the data would have dispersion values of approximately 60. In the
end this turned out to be a slight overestimate, but it’s close enough to be sensible,
especially for the linear models. The model with the largest dispersion (59.5617, just
below the initial estimate) is the linear 1h fit, whilst the quadratic 1h fit has the smallest
dispersion, only 43.42941. Notably, the linear fits have close together dispersion values
(the difference between them is 2.01567), whilst the quadratic fits very much do not (the
difference between them is 9.11545). Thus we could suggest that estimating the dispersion
using a plot of means against variances is more likely to give sensible estimates for linear
fits than quadratic ones. However, the introduction of the extra quadratic term does
appear to reduce overdispersion, sometimes by a large amount (16.13229 in the 1h case).
3.4.3 Standard Errors of Fitted Models
Table 3.2 displays the standard errors for each fitted variable of our eight original fits,
both Poisson and quasi-Poisson. These standard errors have been taken from R summary
outputs for the fitted models. This allows us to use the dispersion values stated in Table
3.1 to verify the relationship between the Poisson and quasi-Poisson standard error values
and thus Equation 3.9. Upon initial inspection, the Poisson standard error values are
each one degree of magnitude smaller than their quasi-Poisson equivalents, which does
fit.
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Figure 3.2: A plot showing the fitted dose-response curves for the PHE (2017) dataset,
superimposed on the full dataset as shown in Figure 1.1. The linear fits are denoted by
straight lines, whilst the quadratic fits are denoted by dashed ones. From [10].
Fit type Time A α β Dispersion, φ
Linear
1h 0.1308 12.5589 - 59.5617
24h 0.1794 1.9373 - 57.5460
Quadratic
1h 0.1124 15.5075 -4.1693 43.4294
24h 0.1414 2.2756 -0.0944 52.5449
Table 3.1: A table of fitted models for the PHE (2017) dataset, showing fit type, time-
point, coefficient values, and the corresponding dispersion values for the quasi-Poisson
models. The model equations being fitted here are Equation 4.9 (linear) and Equation
4.10 (quadratic). Values are rounded to 4 decimal places where necessary.
Using the information given in Table 3.2, we can use Equation 3.9 to validate the
dispersion values from Table 3.1, and thus verify both that our quasi-Poisson fit actually
works and that Equation 3.9 is indeed what is used in R to transform a Poisson model
into a quasi-Poisson model. We chose to test this using the linear and quadratic fits for
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Fit type Time Model SE(A) SE(α) SE(β)
Linear
1h
Poisson 0.0021 0.0208 -
Quasi-Poisson 0.0162 0.1606 -
24h
Poisson 0.0028 0.0049 -
Quasi-Poisson 0.0214 0.0375 -
Quadratic
1h
Poisson 0.0020 0.0558 0.0708
Quasi-Poisson 0.0130 0.3675 0.4664
24h
Poisson 0.0029 0.0151 0.0040
Quasi-Poisson 0.0208 0.1095 0.0292
Table 3.2: A table containing the standard errors for each fitted model for the PHE
(2017) dataset, sorted by fit type, timepoint, and model type, taken as they are from our
R code output. Values are rounded to 4 decimal places where necessary.
the 1h data, due to them having the largest and smallest dispersion values respectively.
Linear:
SEQ(A) =
√
59.5617× 0.0209 = 0.0162
SEQ(α) =
√
59.5617× 0.0208 = 0.1606
Quadratic:
SEQ(A) =
√
43.4294× 0.0020 = 0.0130
SEQ(α) =
√
43.4294× 0.0558 = 0.3675
SEQ(β) =
√
43.4294× 0.0708 = 0.4664
We can clearly see from these calculations that the relationship SEQ(θˆ) =
√
φSEP (θˆ)
(Equation 3.9) holds, thus confirming that the quasi-Poisson functionality in R works as
we would theoretically expect.
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Chapter 4
Dose Estimation
4.1 Yield
In order to estimate the dose, the yield of foci from the sample must first be known. The
yield, y, is found by scoring groups of cells, as discussed in Section 2.2. The number of
cells scored in each sample is referred to as n. (For the PHE (2017) dataset, we have a
constant n throughout. This is not the case in the PHE (2018) dataset.)
The following derivation works for the Poisson case [27]. For a single count Yi, the
Poisson distribution can be written as:
Yi ∼ f(λ, Yi) = e
−λλYi
Yi!
for i = (1, 2, ..., n). We also have that Var(Yi) = λ and SD(Yi) =
√
λ. Therefore the
Poisson likelihood function is given by:
L =
n∏
i
e−λλYi
Yi!
=
e−λλY1
Y1!
× ...× e
−λλYn
Yn!
=
e−nλλ
n∑
i=1
Yi
n∏
i=1
Yi!
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and thus the log-likelihood function is:
ln(L) =
n∑
i=1
ln
e−nλλ
n∑
i=1
Yi
n∏
i=1
Yi!

= −nλ+
n∑
i=1
Yiln(λ)−
n∑
i=1
ln(Yi!).
We can thus find the maximum likelihood estimate (MLE) λˆ by taking the derivative
of the log-likelihood with respect to λ then setting the resultant equation to 0 and solving
for λ:
∂ln(L)
∂λ
= −n+
n∑
i=1
Yi
λ
⇒ −n+
n∑
i=1
Yi
λˆ
= 0
λˆ =
n∑
i=1
Yi
n
= Y¯ = y.
Thus the MLE of the count is the yield.
Knowing the MLE allows us to define the standard error (SE) of the count:
SE(Yi) =
√
λˆ =
1√
n
√√√√ n∑
i=1
Yi,
thus we have:
SE(
n∑
i=1
Yi) =
√√√√ n∑
i=1
SE2(Yi) =
√√√√ n∑
i=1
1
n
n∑
i=1
Yi =
√√√√ n∑
i=1
Yi.
Therefore we can define the sampling variance on the yield of foci per cell for the
Poisson case as:
σ2y = SE
2(y) = SE2(Y¯ ) = SE2
(
1
n
n∑
i=1
Yi
)
=
(
1
n
SE
(∑
Yi
))2
=
(
1
n
√∑
Yi
)2
=
(
1√
n
√∑
Yi√
n
)2
=
(
1√
n
√∑
Yi
n
)2
=
(
1√
n
√
Y¯
)2
=
Y¯
n
=
y
n
∴ σ2y =
y
n
(4.1)
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However, for the quasi-Poisson case we use a GLM property to transform the sampling
variance. From Section 3.2.2 we know that the variance of a GLM is stated by the equation
Var(y|x) = σ2(µ) = φV(µ),
and thus we have that, for an quasi-Poisson fit with our yield y:
Var(y) = φVarP (y).
Therefore, the standard error on the yield for the quasi-Poisson case can be estimated
using
σ2y =
yφ
n
,
where φ is the dispersion parameter.
For our first dataset (PHE (2017)), the results recorded are counts, foci/cell readings
for groups of n = 500 cells. For the second dataset, we were unable to do this due to
multiple scorers (see Chapter 5) and ended up with aggregated data instead.
4.2 Dose Estimation
Now that we have a value for the yield, as well as fitted calibration curves, we can estimate
the dose based on whether we have fitted a linear or quadratic model, using equations that
are based on the fit of the calibration curve. For the datasets we have, linear models are
preferred in the literature, but we have chosen also to give the dose estimation equation
for the quadratic case to test why this is. For the linear case, we have the equation
D =
(y − A)
α
, (4.2)
a rearrangement of Equation 3.6 with D as the subject, whilst for the quadratic case the
dose estimation equation is
D =
−α +√α2 + 4β (y − A)
2β
. (4.3)
This is a rearrangement of Equation 3.7 with D as the subject.
4.3 Reference Sample Ratio
In Ainsbury et al. (2016) [28], a so-called reference sample ratio, whose value is referred
to as r, is included in analysis to scale the data and thus produce a suitable calibration
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curve. This reference sample ratio is created by comparing yields from points on pre-
existing calibration curves with “reference yields” created as controls in a lab situation.
If a reference yield is slightly smaller than the yield on the curve for the same dose, we
adjust by scaling the estimated doses (and thus the curve) up correspondingly. However,
if the reference yield is slightly larger than the yield on the curve, no action is taken.
This is because it is sensible to assume that reference yields are slightly larger as they
are not subject to foci loss (such as through shipping).
The Public Health England factsheet [9] recommends that for best practice “at least
one negative and one positive control” should be created for each time point in the sample.
Here the phrase “negative control” refers to a non-irradiated sample, one that can be said
to have been irradiated to 0Gy. We label this y0Gy. The suggested dose for the “positive
control” sample is 1.5Gy, so this is labelled y1.5Gy. Creating these controls also accounts
for systematic errors between laboratories. These controls should then be scored to yield
pairs of control reference samples, y0Gy ± σy,0Gy and y1.5Gy ± σy,1.5Gy. The standard error
on these samples is calculated the same way as for the yield. Therefore overall, for a
dataset with two time points (say 1h and 24h), one would assume that a minimum of
four reference samples are needed: one irradiated to 0Gy for 1h, one irradiated to 1.5Gy
for 1h, one irradiated to 0Gy for 24h, and one irradiated to 1.5Gy for 24h. However, if
efficiency is required, we do not need two 0Gy control samples - a 0Gy sample serves more
as a measure of background levels of foci counts and thus radiation therefore theoretically
the two 0Gy samples should yield an identical foci count.
When the reference samples have been created, the 0Gy negative control values should
then be compared to the corresponding fitted values of the coefficient A for the dose-
response curve with the matching time point. The 1.5Gy positive control values should
be compared to the 1.5Gy point on said dose-response curve. According to Public Health
England [9], a discrepancy of more than 30% between the reference samples and the points
on the curve is indicative of experimental conditions in the current experiment that do
not “sufficiently match” the experimental conditions at the time that the calibration
curves were created. An alternative method of curve validation can be done by checking
whether the reference samples lie within 95% prediction intervals around our estimated
calibration curves [10]. For this method, our estimated curves are validated if this is
indeed the case. This method does not use the reference sampling ratio and will not be
focussed on otherwise.
When we have curves validated using the first method, i.e. those where the discrep-
ancy between the 1.5Gy points on the predefined calibration curves and the reference
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samples is less than 30%, then we can use the curves to estimate dose. However, we still
account for this discrepancy using a reference sample ratio for scaling.
Our next step is to create the reference sample ratio, r, using the reference sample at
1.5Gy, y1.5Gy, and the yield on the calibration curve that corresponds to a dose of 1.5Gy,
the curve point yC . If y1.5Gy > yC , then r = 1. If y1.5Gy < yC , then r =
yC
y1.5Gy
> 1.
Obviously, if y1.5Gy = yC , then r = 1. Due to the 30% discrepancy upper limit for using
this method, we have that 1 ≤ r ≤ 1.3. Therefore r cannot decrease the value of the
estimated dose, instead keeping it the same or making it slightly larger. Ainsbury et al.
(2016) [28] use a reference sample standard deviation of
√
r, a value that comes from
Poisson assumptions. This can then be used to calculate a corresponding variance, which
is needed later on when calculating the uncertainty on a dose estimate. According to [28],
the standard errors on the reference samples should be estimated in the same manner as
the uncertainty on the sample yield.
Now that we have this ratio r, we can incorporate it into Equations 4.2 and 4.3 as a
scaling factor, giving us two further equations:
1.
D =
(y − A)
α
r (4.4)
(linear, comes from Equation 4.2)
2.
D =
−α +√α2 + 4β (y − A)
2β
r (4.5)
(quadratic, comes from Equation 4.3)
4.4 Uncertainty Analysis
With measurements comes uncertainty, and so naturally a fitted calibration curve itself
has uncertainty. According to the International Atomic Energy Association (IAEA) the
uncertainties associated with a dose-response calibration curve are approximately nor-
mally distributed [5].
4.4.1 Merkle’s Method
When dealing with data that’s been fitted to a Poisson distribution, the subsequent
(Poisson) nature of the yield provides a second component to the uncertainty. It is
still possible to calculate a 95% confidence interval (CI) for the “true” dose, however,
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due to Merkle’s method. This method is detailed in the IAEA’s Dosimetry (Emergency
Preparedness and Response) Manual from 2011 [5], and is well-established for use with the
dicentric biomarker. It uses the confidence limits on the yield and a graph of a calibration
curve. The calibration curve should have uncertainty curves plotted (preferably as dotted
lines) on either side of the dose-response curve. Merkle’s method includes the following
steps:
1. Calculate the yields that correspond to the lower and upper 95% confidence limits
on the observed yield, known as yL and yU respectively.
2. Calculate the dose at which yL crosses the upper uncertainty curve. This is the
lower confidence limit or DL.
3. Calculate the dose at which yU crosses the lower uncertainty curve. This is the
upper confidence limit or DU .
This gives you the widest possible 95% CI for this curve and yield combination.
A proposed refinement to this method to reduce possible overestimation of uncertainty
is to instead use an 83% confidence interval. However, there is little point in attempting
to shrink the interval size without first checking whether this method actually works for
the γ-H2AX histone as well as the dicentric biomarker. Merkle’s method works well for
dicentric data because the distribution of dicentric cells can be said to be equidispersed
with the Poisson distribution [29]. That is, the ratio of the sample variance to the sample
mean is very close to 1:1 and, as Poisson fits are used, each model fitted with dicentric data
has dispersion 1. This is not true for our γ-H2AX data, which has a far larger dispersion
(around 60). Gao (2017) [29] attempted to apply Merkle’s method of generating 95%
confidence intervals to γ-H2AX data with known real doses. In order for the method
to be successful, the expectation was that nearly 95% of the intervals produced should
contain the real doses. For the 1h data, only 10 of the 131 measured yields ultimately
produced intervals that encompassed the real dose (a further 4 yields gave NA as an
answer). This is a success rate of 7.63%. The 24h data fared even worse with only 9
of the 130 yields producing intervals containing the real dose, a success rate of 6.92%.
This is far from satisfactory and suggests that Merkle’s method is insufficient for γ-H2AX
data. Instead, other approaches such as the Delta Method should be considered.
4.4.2 The Delta Method
Assume we have a vector of parameter estimates θ, for which we can fully specify the
variance matrix, V ar(θˆ). Now, assume that we are interested in a real-valued function
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h(θ), and would like to find the variance of this. (This h(θ) will later correspond to the
dose estimator.) From the multivariate Taylor Expansion we have that h(θ) : Rp → R
for a vector θ =

θ1
...
θp
. The MLE of θ is found at the point θˆ.
We know that
Var(θˆ) = Σ,
and can thus use Taylor’s theorem to linearise h(θˆ):
h(θˆ) = h(θ) +∇h(θ)T (θˆ − θ) + c
⇒ Var(h(θˆ)) = ∇h(θ)TVar(θˆ − θ)∇h(θ) + c
= ∇h(θ)TVar(θˆ)∇h(θ)
= ∇h(θ)TΣ∇h(θ)
where Σ is the variance matrix.
Approximating the gradients by their estimates, we have:
Var(h(θˆ)) = ∇h(θˆ)TΣ∇h(θˆ)
=
(
∂h
∂θ1
. . . ∂h
∂θp
)
|θ=θˆ

Σ11 ∗
. . .
∗ Σpp


∂h
∂θ1
...
∂h
∂θp
 |θ=θˆ
.
The non-diagonal terms of the variance matrix Σ correspond to covariances, written as
Σij where i 6= j. If Σij = 0 for i 6= j then the resulting output equation is the initial
MULTIBIODOSE simplification that does not contain covariance terms:
Var(h(θˆ)) =
(
∂h
∂θ1
. . . ∂h
∂θp
)
|θ=θˆ

Σ11
∂h
∂θ1
...
Σpp
∂h
∂θp
 |θ=θˆ = p∑
j=1
(
∂h
∂θj
)2
|θ=θˆΣjj
Therefore the variance of the function is equal to the sum of the squares of the associated
partial derivatives where each squared partial derivative is multiplied by the variance of
the variable used to form the partial when all of the covariances are taken to be 0. We
chose to do this due to the high relative uncertainty of fast biodosimetry. The covariance
components have very small relative magnitude and their contributions have very little
effect [28]. This choice results in a far easier equation to deal with.
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The Delta Method is derived from the ISO standard (2014) and here gives a general
case for estimating the uncertainty on the dose in a quadratic situation where reference
samples are used. It is an immediate consequence of the derivation of the Taylor method
given above.
In the case where
θˆ =

A
α
y
β
 and h(θˆ) = D, we have that
Var(D) =
4∑
j=1
(
∂D
∂θj
)2
|θ=θˆΣjj =
(
∂D
∂A
)2
ΣAA +
(
∂D
∂α
)2
Σαα +
(
∂D
∂y
)2
Σyy +
(
∂D
∂β
)2
Σββ
Var(j) = Σjj = σ
2
j
⇒ σ2D =
(
∂D
∂A
)2
σ2A +
(
∂D
∂α
)2
σ2α +
(
∂D
∂y
)2
σ2y +
(
∂D
∂β
)2
σ2β (4.6)
The following equation is an immediate consequence of the general form of the Delta
Method (see Equation 4.8) as derived above, in the special case θˆ =

A
α
β
y
r

:
σ2D =
(
∂D
∂A
)2
σ2A +
(
∂D
∂α
)2
σ2α +
(
∂D
∂y
)2
σ2y +
(
∂D
∂β
)2
σ2β +
(
∂D
∂r
)2
σ2r (4.7)
This equation is referred to by Ainsbury et al. (2016) as the MULTIBIODOSE simplifi-
cation (specifically the case where r is included) [28]. Obviously, if reference samples are
not being used we remove the corresponding variance term, resulting in Equation 4.6.
This is the general form of the Delta Method:
σ2D =
(
∂D
∂A
)2
σ2A +
(
∂D
∂α
)2
σ2α +
(
∂D
∂y
)2
σ2y +
(
∂D
∂β
)2
σ2β +
(
∂D
∂r
)2
σ2r
+ 2
(
∂D
∂α
)(
∂D
∂β
)
cov(α, β) + 2
(
∂D
∂α
)(
∂D
∂A
)
cov(α,A)
+ 2
(
∂D
∂α
)(
∂D
∂r
)
cov(α, r) + 2
(
∂D
∂A
)(
∂D
∂β
)
cov(A, β)
+ 2
(
∂D
∂A
)(
∂D
∂r
)
cov(A, r) + 2
(
∂D
∂β
)(
∂D
∂r
)
cov(β, r)
(4.8)
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We prefer the MULTIBIODOSE simplification to the general form of the Delta Method
due to the potential availability of the covariance values. These covariance terms would
need to be derived from a previously fitted calibration curve, and may not be reported in
some scenarios where we are given curves and do not fit them ourselves. We do have these
values for our fitted models, but they are very small relative to the individual variances
and have little impact on the uncertainty on the dose. (This may be true for all models,
but requires further research.) Uncertainty analysis using the Delta Method may also be
referred to as the GUM method, due to research by the Joint Committee for Guides in
Metrology [30].
4.4.3 Application of the Delta Method
The uncertainty on the dose, σ2D, can be calculated using the variances, covariances, and
partial derivatives of the variables in the dose estimation equations (A,α, y, r, as well as
β for the quadratic equation).
For scenarios where a reference sample ratio is not used, the two dose equations:
1. D = (y−A)
α
(linear, also Equation 4.2)
2. D =
−α+
√
α2+4β(y−A)
2β
(quadratic, also Equation 4.3)
have partial derivatives taken then are substituted as appropriate into the Delta Method
(also Equation 4.6)
σ2D =
(
∂D
∂A
)2
σ2A +
(
∂D
∂α
)2
σ2α +
(
∂D
∂y
)2
σ2y +
(
∂D
∂β
)2
σ2β
to give:
1.
σ2D =
1
α2
σ2A +
1
α2
σ2y +
(
A− y
α2
)2
σ2α (4.9)
(linear)
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2.
σ2D =
1
α2 + 4β(y − A)σ
2
A
+
1
α2 + 4β(y − A)σ
2
y
+
1
4β2
(
α√
α2 + 4β(y − A) − 1
)2
σ2α
+
1
β2
(
(y − A)2
α2 + 4β(y − A) +
α(y − A)
β
√
α2 + 4β(y − A) +
y − A
β
+
α2
4β2
+
α
√
α2 + 4β(y − A)
2β2
+
α2 + 4β(y − A)
4β2
)2
σ2β
(4.10)
(quadratic)
When a reference sample ratio is included, the two dose equations:
1. D = (y−A)
α
r (linear, also Equation 4.4)
2. D =
−α+
√
α2+4β(y−A)
2β
r (quadratic, also Equation 4.5)
have partial derivatives taken then are substituted as appropriate into the Delta Method
(also Equation 4.7)
σ2D =
(
∂D
∂A
)2
σ2A +
(
∂D
∂α
)2
σ2α +
(
∂D
∂y
)2
σ2y +
(
∂D
∂β
)2
σ2β +
(
∂D
∂r
)2
σ2r
to give:
1.
σ2D =
r2
α2
σ2A +
r2
α2
σ2y +
r2(A− y)2
α4
σ2α +
(y − A)2
α2
σ2r (4.11)
(linear)
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2.
σ2D =
1
2β2
(α2 + 2β(y − A)− α
√
α2 + 4β(y − A))σ2r
+
r2
α2 + 4β(y − A)σ
2
A
+
r2
α2 + 4β(y − A)σ
2
y
+
r2
4β2
(
α√
α2 + 4β(y − A) − 1
)2
σ2α
+
r2
β2
(
(y − A)2
α2 + 4β(y − A) +
α(y − A)
β
√
α2 + 4β(y − A) +
y − A
β
+
α2
4β2
+
α
√
α2 + 4β(y − A)
2β2
+
α2 + 4β(y − A)
4β2
)2
σ2β
(4.12)
(quadratic)
In order to calculate these uncertainty values (for a given input dose, model, foci
count, and number of cells scored at that dose), we used R code. This is the code for
the simplest scenario, the linear situation without a reference sample ratio/where the
reference sample ratio is taken to be 1:
s2D.li<- function(y,fit,n,count){
A1<- fit$coefficients[[1]]
a1<- fit$coefficients[[2]]
d1li<-summary(fit)$dispersion
s2A1<- vcov(fit)[1,1]
s2a1<- vcov(fit)[2,2]
s2y1<- d1li*y/n
q1<-s2A1/a1^2
q2<-s2y1/a1^2
q3<-(A1-y)^2*s2a1*a1^-4
q=c(q1,q2,q3)
names(q)=c("A","y","alpha")
barplot(q, xlab=expression(paste("Coefficients of ", sigma^2)),
ylab="Value",main="Linear")
sigma2D1<- q1+q2+q3
print(q)
return(sigma2D1)
35
}Here A1 is the intercept coefficient A and s2A1 its variance σ2A, whilst a1 is the slope
coefficient α with variance σ2α inputted as s2a1. s2y1 is the variance σ
2
y of the yield. We
are implementing Equation 4.11 here.
The full R scripts for the other scenarios can be found in Appendix C.
We decided to split the calculations up into what we chose to refer to as “terms”:
the coefficients of each variable’s variance σ2 multiplied by the variance itself, which
allows for easier error checking (and reduces the amount of calculations done at a time
in R). The A, α, and β terms are referred to as “coefficient” terms, as the value of the
labelling coefficient is generated by the fitted GLM. For instance, 1
α2+4β(y−A)σ
2
A is the A
term from the quadratic Delta Method equation that doesn’t include a reference sample
ratio (Equation 4.10). In this case, σ2A is the variance of A, the intercept variable, and
1
α2+4β(y−A) is its associated coefficient. Our R formula then sums the term values to get
an output variance value.
We also realised that the linear expression without reference sample ratio could be
reformulated into a quadratic equation with terms of y:
σ2D =
σ2A
α4
y2 − 2Aσ
2
α
α4
y +
1
α2
(
σ2A + σ
2
y +
A2
α2
σ2α
)
(4.13)
then coded this separately in a similar manner. We chose to label this the “y reformula-
tion”.
Upon seeing (and subsequently being surprised by) the (unexpectedly large) uncer-
tainty values that the code produced for our original dataset, we chose to graph the
terms, plotting each one separately on a bar chart. This allowed us to see which ones
contributed most or least to the overall uncertainty for each dose. If one coefficient term
contributes significantly more to the uncertainty than all of the others, this implies that
the preferable fitted model is one that does not contain that term. As shown later in
Figure 4.1, the β (or quadratic) term gives a significantly larger uncertainty than the
other terms, so we should prefer a linear fitted GLM over a quadratic one.
4.5 Examples
4.5.1 Dose Estimation
Now that we have the coefficients of our fitted model, we can use Equations 4.2 and
4.3, as specified earlier to estimate the dose of exposure for a chosen yield. We initially
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choose to do this four times (linear and quadratic scenarios for both timepoints) to give
us four comparative doses. We can then double check our calculated doses against the
calibration curves. Our four dose equations are as follows:
1h:
Linear:
D =
(y − 0.1308)
12.5589
Quadratic:
D =
−15.5075 +√15.50752 + 4×−4.1693 (y − 0.1124)
2×−4.1693
=
−15.5075 +√15.50752 − 16.6773 (y − 0.1124)
−8.3386
24h:
Linear:
D =
(y − 0.1794)
1.9373
Quadratic:
D =
−2.2756 +√2.27562 + 4×−0.0943 (y − 0.1414)
2×−0.0944
=
−2.2756 +√2.27562 − 0.3774 (y − 0.1414)
−0.1887
For an arbitrarily chosen yield of 5 foci/cell, y = 5, we can thus estimate the doses
for all four scenarios. This yield was chosen as it is large enough to give very different
dose estimates for the two different timepoints, as well as hopefully providing differing
dose estimates between the pairs of linear and quadratic fits. All doses stated here are
rounded to four decimal places.
1h:
Linear:
D =
5− 0.1308
12.5589
= 0.3877Gy
Quadratic:
D =
−15.5075 +√15.50752 − 16.6773 (5− 0.1124)
−8.3386
=
−15.5075 +√158.9705
−8.3386
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D = 0.3477Gy
24h:
Linear:
D =
5− 0.1794
1.9373
= 2.4884Gy
Quadratic:
D =
−2.2756 +√2.27562 + 4×−0.0944 (5− 0.1414)
2×−0.0944
=
−2.2756 +√3.3445
−0.1887
D = 2.3675Gy
As expected, the estimated doses for the 24h scenarios are significantly larger than
those for the 1h scenarios, with a difference of over 2Gy between timepoints for each
model type.
4.5.2 Uncertainty Quantification
Initially we had twelve scenarios, six Poisson and six quasi-Poisson. The scenarios we
used were for both timepoints and were the standard linear and quadratic fits (Equations
4.9 and 4.10 respectively), as well as the aforementioned “y reformulation” (Equation
4.13) above. We chose not to include the reference sampling ratio at this time, but did
test these scenarios with two different yields (5 foci/cell and 1 foci/cell). To decide which
scenarios were most beneficial, we chose to code and plot all of them (Figures D.1 and
D.3 in the Appendices respectively) and then analyse those plots. Unsurprisingly, the y
reformulation had far more uncertainty attached to the “constant” term than either the
y2 or y coefficients, which is to be expected due to the greater number of terms involved
(three, compared to one each in the other two cases). Upon further inspection of those
twelve initial plots, we decided to prioritise a set of four plots and their corresponding
uncertainty equation scenarios. These four scenarios are the standard linear and quadratic
quasi-Poisson fits for both the 1h and 24h timepoints, and are shown later in Figures
4.1 (yield of 5 foci/cell) and D.2 (yield of 1 foci/cell). Ultimately, we decided that
although interesting, the y reformulation is of less immediate interest compared to the
more “conventional” way of splitting up the uncertainty equations. The quasi-Poisson fits
are of more interest to us than the Poisson ones as the total variance for a quasi-Poisson
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fit will be significantly larger than the Poisson total variance due to Equation 3.8. This
equation can also be applied to each parameter in the model separately, therefore the
relative size of the bars on a corresponding pair of plots (one Poisson and one quasi-
Poisson) will be the same. Using the plots with larger values allows us to see just how
big the variances for a certain yield (and thus dose estimate) could get.
As in Section 4.5.1, we use a sample yield of 5 foci/cell to begin with. (A second yield
of 1 foci/cell is shown in Appendix D, along with the full set of plots for all 12 scenarios
for the yield of 5 foci/cell.) We used the R code given in Section 4.4.3 and Appendix
C to calculate the values for each “coefficient” and ultimately create the plots shown in
Figure 4.1.
Fit type Time
Coefficients of σ2 Total Standard
A y α β uncertainty error
Linear
1h 1.6565×10−6 3.7763×10−3 2.4581×10−5 - 3.8025×10−3 6.1665×10−2
24h 1.2197×10−4 1.5334×101 2.3196×10−3 - 1.5578×10−1 3.9469×10−1
Quadratic
1h 1.0646×10−6 2.7319×10−3 1.0270×10−4 1.1143×10−1 1.1427×10−1 3.3803×10−1
24h 1.2947×10−4 1.5711×10−1 2.0101×10−2 3.4800×101 3.5077×101 5.9226×100
Table 4.1: The individual “term” values for Figure 4.1, as well as their sum, the total
uncertainty for the estimated dose. All values given in standard form, to five significant
figures.
It is clear from Table 4.1 that overall the quadratic fits have significantly larger total
uncertainties than the linear ones, typically by two orders of magnitude. The uncertainty
associated with the β term provides the bulk of these larger uncertainty values, and,
in the case of the 24h quadratic fit, has a value of over 30. If we construct confidence
intervals of ±2 standard errors for the doses estimated from our quadratic fits, we end
up with 0.3476761 ± 0.6760696 for the 1h fit, and 2.367536 ± 11.84517 for the 24h fit.
Clearly, these are not possible given that the minimum possible dose for exposure is 0Gy.
As well as this, the width of the 24h quadratic fit interval is so large as to be effectively
useless, considering that the maximum dose used in the dataset is 4Gy, due to how hard
it is to count foci beyond that point. The size of the uncertainties associated with the β
terms provides evidence to reject quadratic fits in favour of linear ones for this biomarker.
4.5.3 Reference Sample Ratio
We already know that if y1.5Gy > yC , then r = 1. If y1.5Gy < yC , then r =
yC
y1.5Gy
> 1.
Obviously, if y1.5Gy = yC , then r = 1.
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For this example, we are using raw data from our second γ-H2AX histone dataset
(PHE (2018)) as reference samples. This dataset is the focus of Chapter 5, but little
knowledge of it is required here as we are only using the four pieces of sample data listed
in Table 4.2. One quirk that must be noted is that since we are only using two reference
samples per time point any quadratic curves that are rejected will be replaced with linear
ones.
Dose (Gy) Time (h) Yield (foci/cell) 30% Discrepancy Interval
0
1 0.34 (0.238, 0.442)
24 0.585 (0.4095, 0.7605)
1.5
1 5.02 (3.514, 6.526)
24 2.915 (2.0405, 3.7895)
Table 4.2: A table of the raw data from the PHE (2018) dataset used as reference samples
(y0Gy for the 0Gy yields and y1.5Gy for the 1.5Gy yields) in Section 4.5.3, along with the
interval that gives a 30% discrepancy limit on each side.
Dose (Gy) Time (h) Fit type Yield (foci/cell)
0
1
Linear 0.1308
Quadratic 0.1124
24
Linear 0.1794
Quadratic 0.1414
1.5
1
Linear 18.9691
Quadratic 13.9927
24
Linear 3.0853
Quadratic 3.3424
Table 4.3: A table of the calculated calibration yield values (yC) used in the reference
sampling ratio examples in Section 4.5.3, rounded to 4 decimal places where necessary.
Initially we used all four of our calibration curves to calculate yield values at the
chosen control dose points of 0Gy and 1.5Gy, as shown in Table 4.3. These are our
calibration yields. We then cross-referenced these with the discrepancy intervals given in
Table 4.2, and it is apparent from doing so that only the two 24h, 1.5Gy fitted values
are less than 30% above or below (in both cases, above) the reference yield values. This
means that none of the curves can be validated fully overall. However, one can argue that
the positive control sample is of greater importance than the negative (0Gy) one. Both
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the value of A and its 30% discrepancy interval are comparatively small, and it would be
undesirable to throw a curve away due to that mismatch [10]. Therefore we ultimately
chose to calculate a pair of reference sampling ratios for our two “validated” yields. In
both of these cases our sample yield is greater than the reference yield, so
r =
yC
y1.5Gy
.
For the 24h linear fit at a dose of 1.5Gy:
r24L =
3.0853
2.915
= 1.0584.
For the 24h quadratic fit at a dose of 1.5Gy:
r24Q =
3.3424
2.915
= 1.1466.
Using these values we would then be able to adjust the dose equations and calculate
dose estimates (rounded to 4 decimal places) for a yield of 5 foci/cell:
Linear:
D24L =
(y − 0.1794)
1.9373
r24L
=
(y − 0.1794)
1.9373
1.0584
= 0.5463 (y − 0.1794)
D24L = 2.6337Gy
Quadratic:
D24Q =
−2.2756 +√2.27562 + 4×−0.0944 (y − 0.1414)
−0.1887 r24Q
=
−2.2756 +√2.27562 + 4×−0.0944 (y − 0.1414)
−0.1887 1.1466
= −6.0764
(
−2.2756 +
√
2.27562 + 4×−0.0944 (y − 0.1414)
)
D24Q = 2.7147Gy
Both of these estimates are larger than those from the other 24h equations in Section 4.5.1,
with a larger difference between the original quadratic dose estimate and the adjusted
one. This can be explained by the larger reference sampling ratio value, and shows that
greater upward scaling is needed for the quadratic fit than for the linear one.
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Due to the negative control mismatch, we could alternatively construct replacement
calibration curves using the reference yields. These curves, constructed from 2 points,
are y = 3.12D+ 0.34 for the 1h data and y = 1.553333D+ 0.585 for the 24h data. With
regards to the uncertainty, the relative proportions of the existing terms would remain
the same, as each one is multiplied through by r2.
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Figure 4.1: A series of four plots showing the contribution to the overall uncertainty for
each “term” in a given scenario with a yield of 5 foci/cell, accompanying the code given in
Section 4.5.2 and Appendix C. The four scenarios included are all quasi-Poisson models.
The top row shows term by term uncertainty for linear scenarios at both timepoints (1h
and 24h), whilst the bottom row shows the pair of corresponding quadratic fits.
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Chapter 5
Introducing a Second Dataset
5.1 Background
The second dataset that we have worked with was also provided by Public Health England
and uses blood lymphocytes from a single donor, whose blood was taken at three different
times. It will henceforth be referred to as the PHE (2018) dataset. Irradiation was
performed in vitro, with 250kVp X-rays as the radioactive source, and the slides were
then manually scored. This dataset contains measured foci counts for four design doses:
0.75Gy, 1.5Gy, 3Gy, and 4Gy, as well as a control dose, 0Gy. All of these doses had
samples scored at three different time points: 1h, 4h, and 24h. The initial dataset
consists of both full body and simulated partial body scored samples, at 10% intervals,
but as we are focussing on full body irradiation we chose to separate out the 0% and
100% irradiation data for use in model fitting. We later decided to code this in R using
an indicator variable whose value is 0 if the sample hasn’t been exposed to radiation or
1 if it has been. The amount of 0Gy data is significantly larger than the amount of data
for any other dose, because the experiment was set up so that every dose & time point
combination has two sets of data, one irradiated and one not.
The intended number of cells scored for each dose & time point combination was 200.
However, there is some data missing due to equipment (specifically slide) issues when
scoring. The 4Gy data is especially affected by this, with no irradiated 1h or 24h data
remaining. One reading is missing for the control data at the 24h time point within
the 1.5Gy sample. There are also issues with the 3Gy data: 4 readings are missing
for the irradiated 4h data, whilst 147 readings are missing for the irradiated 1h data,
nearly three-quarters of the scored cells for that dose & time point combination. We
thus have potential issues with the usefulness of the 0.75Gy irradiated 1h data due to the
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significantly reduced sample size, and the 4Gy irradiated data overall only exists for one
of the 3 timepoints, reducing the availability of comparison.
5.2 Work Done
5.2.1 Scorers
From initial information given, we know that there are two scorers, one of whom routinely
recorded higher foci counts than the other at a dose of 0Gy. The raw data labels these
“Scorer 1” and “Scorer 2”. Scorer 1 was responsible for 16 of the 22 sets of readings, whilst
Scorer 2 was responsible for the other 6 sets. We chose to plot each scorer’s measured
foci counts for a dose of 0Gy, and from these plots (Figure 5.1) we can see that there is a
clear difference between the counts (and thus the yields) that they recorded. Scorer 2’s
maximum count is only 3 foci, recorded 3 times, whilst Scorer 1 not only records a count
of 3 foci many more than 3 times - they also have a maximum recorded count of 7 foci.
Knowing which scorer records higher foci counts makes it easier for us to normalise the
data to account for the differences between the two of them.
After observing in Figure 5.1 that there appeared to be a difference between scorers,
we then wanted to determine whether or not this was large enough to be statistically
significant. To do this we performed a Welch’s two sample t test (which does not assume
equal variances) using the 0Gy data. Our null hypothesis is that the population means for
the two groups are equal, or µ1−µ2 = 0. This gave us a t value of 16.123 on 2245.2 degrees
of freedom, with a stated p value of p < 2.2 × 10−16. As this p value is less than 0.05,
we reject this null hypothesis. A 95% confidence interval for the difference between the
group means µ1−µ2 was given as (0.3994089, 0.5100251), and the difference between the
sample estimates was 0.547217− 0.092500 = 0.454717. Therefore we have a statistically
significant difference between the two sets of data, which needs to be accounted for in
order to successfully fit models for the whole dataset.
5.2.2 Data Cleaning
To correct for the differences between the scorers, PHE scientists applied some initial
normalisation to the data, relative to the 0Gy readings and accounting for differences
between scorers. A screenshot of some of this data is given in Appendix A, specifically
in Figure A.2. When analysing the data we initially calculated the mean value of the
normalised 0Gy data. However, this turned out to be −0.0001709045, which is less than
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Figure 5.1: A pair of plots with equal scales showing the foci counts obtained by each
scorer at a dose of 0Gy, sorted by index number in the PHE (2018) dataset. The data
that will be used for model fitting is an aggregated form of this.
0. This presents an issue for fitting both Poisson and quasi-Poisson models, as mean
values below zero violate the modelling assumptions.
To correct for the many negative values in the normalised original data, especially
the 0Gy data, we calculated the mean of all the original scored counts for the 0Gy
values (note: not the normalised values) and summed it with each normalised value.
The resulting set of (hundreds of) values are known as the “corrected” ones. We then
aggregated the data by taking the mean of the corrected values for each cell, resulting
in 22 data points. However, 12 of those data points correspond to a dose of 0Gy, and it
turned out that all 12 had the same corrected value of 0.3955815, meaning that only 11
distinct data points will be visible on any plotted graph.
46
5.3 Examples
5.3.1 Model Fitting
There are some potential issues when fitting a GLM to this data. For a given dose, we have
at most 8 data points, 4 of which have the same value. Thus we only have a maximum of
5 distinct values to fit dose-response curves with, which is very low. Our initial attempts
to fit models suffered as a result of this, and the presence of underdispersion was a useful
indicator of our errors.
Instead we ultimately decided to try and jointly fit the time points together. In this
model we took 1h as the “default” exposure time and used terms containing indicator
functions to produce variables that also applied only when the time points were 4h or 24h
for both the intercept and the slope coefficients. We also changed the response variable
from the “corrected” values to their product with n, the total number of readings in each
cell. We labelled this new variable “ncorr”.
The R code from our fitted model is as follows:
fit.ndt.li.quasi<-glm(ncorr~-1 + n + ndose.actual + ntime4+ntime24
+ntime4dose.actual+ntime24dose.actual,
family="quasipoisson"(link="identity"), data=pheh2axc)
fit.ndt.li.quasi
fit.ndt.li.quasi$coefficients
#n ndose.actual ntime4 ntime24
#0.43288416 2.53297659 0.07983618 -0.03947914
#ntime4dose.actual ntime24dose.actual
#-1.26913989 -1.49237194
summary(fit.ndt.li.quasi)$dispersion
#[1] 49.73107
This new dispersion value is far closer to the expected 60 and shows evidence of overdis-
persion, as expected.
We can split our new fitted model into three linear models, one for each timepoint,
by summing the relevant terms, as shown in Table 5.1. These fits are also plotted below
as fit lines on a graph of the aggregated data.
To verify that fitting the time points together was a suitable idea, we also tested
it with our earlier dataset. The resultant linear fits produced were very similar to our
established ones, suggesting that this method is worth using for another dataset with
fewer aggregated data points.
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Time Intercept, A Slope, α
1h 0.43288416 2.53297659
4h 0.5127203 1.263837
24h 0.393405 1.040605
Table 5.1: A table of the coefficient values for the three linear dose-response curves
calculated from the joint quasi-Poisson model fitted using the PHE (2018) dataset.
Of our 3 fits, the 4h one has the highest intercept value, whilst the 1h fit has the
greatest slope. These slope values follow the general established pattern: the greater the
amount of time since the sample’s exposure to radiation, the lower the value of the slope
coefficient. Notably, the difference between the 1h and the 4h slope coefficient values is
far larger than the difference between the 4h and the 24h values.
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Figure 5.2: A plot showing the fitted dose response curves for the aggregated data from
the PHE (2018) dataset, along with the aggregated data itself. The 1h line and data
points are shown in black, the 4h in green, and the 24h in red.
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Data Time Intercept, A Slope, α Notes
Public Health England (2018)
1h 0.4329±0.1633 2.5330±0.3884
4h 0.5127±0.1734 1.2638±0.2111
24h 0.3934±0.1533 1.0406±0.2572
Public Health England (2017)
1h 0.1308±0.0162 12.5589±0.1606
24h 0.1794±0.0214 1.9372±0.0375
Rothkamm et al. (2013)
4h
0.10±0.09 1.47±0.22 1L
0.12±0.07 3.10±0.21 2L
0.71±0.19 1.08±0.17 5L
0.35±0.26 1.48±0.26 5B
24h
0.08±0.02 0.54±0.04 1L
0.09±0.02 0.78±0.03 2L
0.46±0.09 0.94±0.09 5L
0.13±0.03 0.70±0.05 5B
Ainsbury et al. (2016)
4h 0.6454±0.0822 2.4686±0.0676 HDR
24h 0.1060±0.0379 0.8227±0.0455 HDR
Table 5.2: Table of linear fits for comparison purposes including the standard errors for
each term. For the Rothkamm et al. (2013) data the number given in the notes refers to
the number of the lab that the curve was calibrated at. The letter refers to the sample
type, either B for a (full) blood sample or L for lymphocytes. The Ainsbury et al. (2016)
data in the bottom two rows of the table is the data for the γ-H2AX sample recorded in
that paper, which is itself cited as being from Rothkamm et al. (2013).
5.3.2 Comparing Fitted Models
When selecting which fits to use from the data presented by Rothkamm et al. (2013)
[7] we chose only to use those where the cells had been scored manually, to match the
manual scoring performed for the PHE datasets. We are also only comparing linear fits
here, due to the greater number available for comparison.
Aside from our new fitted dataset, we only have one other 1h dataset for comparison
(our other PHE dataset), and the old dataset has an intercept roughly a third of the
height of the new. The slope of the old is approximately 5 times greater than that of
the new. Overall, there is very little to compare here. This lack of samples may be due
to the relative impracticality of a 1h time point, as in a real life situation it would be
unrealistic to collect and score a sample from a patient within this time frame.
At first glance, the coefficients for our new 4h fit seem to make sense compared to
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the pre-existing ones. The intercept of our new fit is high compared to labs 1 and 2, but
it is sufficiently close in value to the other data (within 0.2 either side) to not feel out
of place. It is within 1 standard error for 3 out of the 6 models it is being compared
to. However, the 4h slope for our new dataset is the second smallest slope value for that
timepoint, although it is within 1 standard error for the lab 1 model and the lab 5 blood
sample model, so there isn’t too much cause for concern.
When it comes to our new 24h fit, the intercept value is unexpectedly high. It is
closer to the lab 5 lymphocyte data, which some may suspect to be anomalous, than any
of the other 5 intercept values. Our intercept value is similar to the one we fitted for 1h
data though, which could suggest a relatively constant background rate throughout. It
is still over twice the size of the smaller 5 intercept values. On the other hand, our new
slope value is just over half that of the old 24h PHE data and just over the upper interval
limit for lab 5 lymphocytes. Compared to all other fits our new slope value is large but
not significantly so.
We know that γ-H2AX dose-response curves are strongly time dependent, and have
now seen these trends across datasets, so how would we deal with data where the time
since exposure is unknown? Yield can be used to calculate a dose and the uncertainty on
that dose, but here we run into a practical issue: we don’t know if a low foci yield comes
from a low dose or a high dose but with a long period of time between radiation and
sampling. Horn, Barnard, and Rothkamm (2011) address modelling foci decay over time
[22], and equations like those they suggest could be of use, but further research is needed
to estimate decay time. Here again for unknown time and dose the primary complication
remains that their effects are interlinked and difficult to separate.
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Chapter 6
Further Topics & Conclusions
6.1 Further Topics
In this section we will address other radiation dose modelling topics that did not form
part of our earlier modelling and analysis but are still of interest.
6.1.1 Partial Body Exposure
It is easiest statistically to assume that an entire body has been homogeneously ex-
posed to ionising radiation. However, this does not reflect real life: according to Horn,
Barnard, and Rothkamm (2011) [22], “most human radiation exposures are partial body
exposures”. Partial body exposure occurs when a dose of ionising radiation is received
inhomogeneously across a person. Not all of the person may have been exposed. Using a
whole body dose estimate for these partial body exposures can prove dangerous, due to
both the underestimation of the peak dose delivered to a body part and the potential for
this resulting in incorrect triage or treatment for the patient [22]. For instance, highly
localised exposure to large doses of ionising radiation may result in severe tissue damage.
Early clinical intervention could potentially reduce or even prevent this, so knowing the
magnitude of the peak dose delivered could have a significant impact on patient health.
Typically, partial body estimation is simulated in lab conditions by mixing two blood
samples, one irradiated and one not, in stated and easily controlled proportions (e.g.
40% irradiated and 60% not). These two blood samples do not have to be from the same
donor - Hilali et al. (1991) irradiated a blood sample from a male donor and mixed it
with a not irradiated blood sample from a female one, later using the Y chromosome
from the male donor as an indicator [21].
For the dicentric assay, which is typically modelled using a Poisson distribution for
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whole body exposure, overdispersion is a hallmark of partial body exposure. Whole body
exposure to sparsely ionising radiation leads to aberrations being induced randomly in
all cells, whilst a partial body exposure results in both a high number of cells without
aberrations and those with multiple dicentrics [22]. This results in overdispersion for
scored cells, which can be used to estimate the extent of the irradiation [4]. We assume
that a given blood sample consists of two portions, or fractions: a fraction of Poisson
distributed dicentrics from the irradiated part, and a fraction of dicentric-free cells from
the remaining unirradiated part of the body. (Note: this assumes that the irradiation of
the exposed section is homogeneous.) An iterative maximum likelihood method can then
be used to approximate the fraction, f , of the scored cells that were irradiated and the
corresponding mean yield, y (Hilali et al. refer to this y as the “aberration frequency in
[the] population” [21]):
y
1− e−y =
X
N −N0 (6.1)
f =
X
Ny
,
where N is the total number of cells scored, X is the number of dicentrics observed, and
N0 is the number of cells without dicentrics. We can only solve Equation 6.1 iteratively.
Standard dose-response curves can then be used to estimate the mean dose to the irradi-
ated fraction of the body [4]. However, we cannot derive the actual fraction of the body
exposed to radiation without correcting for the effects of mitotic delay and apoptosis
(interphase death), the factors which can reduce cells’ ability to reach metaphase in a
48h culture. This reduction of the observable irradiated fraction is dose-dependent and
can be calculated using:
P = e
−D
D0 ,
where P is the surviving fraction, D is the absorbed dose, and D0 is the dose required
to reduce the number of irradiated cells to 37% of the original due to the factors men-
tioned above, assuming an exponential dose-effect relationship. The corrected fraction of
irradiated cells, F , can thus be calculated using:
F =
f/P
1− f + f/P .
This is known as the contaminated Poisson method.
An alternative available method for dose estimation in a partial body exposure situ-
ation is the Qdr method. It uses the yield of aberrations (dicentrics and rings) in just
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the damaged cells to approximate the dose delivered in the exposure, assuming that
these aberrations are indeed caused by the exposure to ionising radiation and thus were
present when it took place. The expected yield, labelled Qdr, of aberrations amongst the
damaged cells, Nd, is given by:
Qdr =
X
N − d =
y1
1− e−y1−y2 ,
where y1 and y2 are yields of dicentrics plus rings and excess acentric aberrations, respec-
tively [4]. The limitations of this method include the lack of information on the size of the
irradiated fraction, as well as two incorrect assumptions: that the background frequency
of dicentrics and rings is 0, and that excess acentrics fit a Poisson distribution. However,
the two methods detailed above still have a good level of agreement with each other.
The γ-H2AX histone assay has been shown to be able to identify a recent partial
body exposure of any dose, as well as any remaining foci several days after a high dose
partial body exposure. Both the contaminated Poisson and Qdr methods have been used
with this assay, although according to Horn, Barnard, and Rothkamm, the contaminated
Poisson method was generally more accurate (judged by p values from Pearson’s chi-
square goodness of fit tests).
6.1.2 Full Count Distributions
Zero inflation is a phenomenon that is frequently related to overdispersion, and like
overdispersion it can reduce the suitability of a Poisson fit. As discussed in Section
3.2.1, zero inflation occurs when the number of zeros in a sample significantly exceeds the
expected amount. For count data, this amount is the expected number of zeros generated
by a Poisson distribution with the same mean as the sample. Due to the relationship
between them, distributions that account for overdispersion (e.g. compound Poisson
and mixed Poisson distributions) will, to some extent, account for zero inflation too.
This still generates an insufficient amount of zeros for many real life scenarios though,
including agricultural, medical, and manufacturing ones. To account for this, we can use
models that have been specifically designed to deal with zero-inflated count regression.
Zero-inflated count models aim to account for the excess zeros by modelling data as a
combination of two distributions: one that takes a single value at zero, then a count
distribution for all non-zero values [27]. The two most commonly used regression models
of this type are the zero-inflated Poisson (ZIP) model and the zero-inflated negative
binomial (ZINB) model. Although not discussed earlier, these models can also be used
for partial body irradiation scenarios.
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To define a ZIP model, we take d blood samples from a healthy donor and irradiate
them with several doses Di, i = 1, . . . , d. For each irradiated sample of n cells, let Yij,
i = 1, . . . , d, j = 1, . . . , ni be our response variable which represents the observed number
of dicentrics at dose level i for cell j. We can then define the ZIP regression model as:
P (Yij = yij) =
pi + (1− pi)e−λi , yi = 0(1−pi)e−λiλyiji
yij !
yij > 0
where 0 ≤ pi ≤ 1 and λi > 0. The ZIP model’s expectation and variance are defined by
E(Yij) = (1− pi)λi = µi and V ar(Yij) = (1− pi)λi(1 + piλi), where λi refers to the mean
of the underlying Poisson distribution and pi is the mixture parameter (also referred to
as the “zero-inflation parameter”). Both λi and pi can depend on vectors of covariates
[23]. As V ar(Yij) = µi(1 + piλi) ≥ µi, zero inflation can be considered to be a special
form of overdispersion.
A ZIP model may provide a better fit for overdispersion that is linked to a large
number of zeros with regards to the Poisson model. This type of zero-inflated regression
model assumes that the observed zeros have two different origins: one group of zeros is
produced at random by the Poisson distribution, whilst the other group are considered to
be “structural”. These so-called “structural” zeros, with proportion pi, must be justified
by the nature of the data, such as non-irradiated lymphocytes following a partial body
exposure [23]. However, ZIP models may not be suitable for scenarios with multiple
sources of excess zeros, such as densely ionising radiation. Here the ZINB regression
model may be more appropriate. Introduced by Greene in 1994, the ZINB model is an
extended version of the negative binomial model for excess zero count data. For situations
where overdispersion is due to both an excess of zeros and heterogeneity of data, the ZINB
regression model is often more suitable than the ZIP one.
The ZINB model with response variable Yij (i = 1, . . . , d; j = 1, . . . , ni) has probability
mass function:
P (Yij = yij) =
pi + (1− pi)(1 + αλ
c
i)
−λ1−ci /α, yij = 0
(1− pi)Γ(yij+λ
1−c
i /α)
yij !Γ(λ
1−c
i /α)
(1 + αλci)
−λ1−ci /α(1 + λ−ci /α)
−yij , yij > 0
where α > 0 is an overdispersion parameter, and the index c ∈ 0, 1 gives the form of the
underlying distribution. Oliveira et al. (2015) denote these two models as ZINB1 and
ZINB2 respectively [23]. In general, the ZINB model has mean E(Yij) = (1− pi)λi = µi
and variance V ar(Yij) = (1− pi)λi(1 + piλi + αλci). The ZINB model reduces to the ZIP
model as α → 0. This is analogous to the relationship between the negative binomial
and Poisson distributions.
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Zero-inflated models are not the only ones that have been considered to deal with
overdispersed data. Aside from the Poisson and negative binomial distributions, Oliveira
et al. (2015) consider four other types of distributions: the Neyman type A distribution,
the univariate rth-order Hermite distributions, Poisson-inverse Gaussian distributions,
and Po´lya-Aeppli distributions.
6.2 Conclusions
In this thesis we have successfully analysed an unpublished internal factsheet from Public
Health England [9] entitled “Dose and uncertainty estimation with the gamma-H2AX as-
say”, which briefly and succinctly discusses suggested procedures to estimate doses from
blood or lymphocyte samples using the γ-H2AX assay biomarker. We explored the tech-
niques detailed on it with reference to the field of biodosimetry as a whole then applied
them to two datasets from Public Health England. The first dataset, PHE (2017), our
primary dataset, was used to demonstrate and illustrate the techniques and procedures
described in the factsheet. The second dataset, PHE (2018), was then used to check
that the methods described work for scenarios other than the first dataset. The meth-
ods described guide the user through calibration curve construction, dose estimation,
and uncertainty estimation for a given dataset, including the introduction of a reference
sampling ratio to validate the fitted calibration curves.
Overall the methods included on this factsheet not only work, but are of use when
constructing and validating dose-response curves, as well as estimating exposed doses and
the uncertainty on them. The linear dose-response curves fitted using both PHE datasets
follow the general trend established in the literature (as shown in Section 5.3.2), namely
that the value of the slope (α) coefficient decreases with increased time. The intercept
(A) coefficient appears to remain fairly similar throughout for models fitted using the
same data with little obvious consistent time-based effect. However, these values differ
between datasets to an extent where we would not feel comfortable using them to assess
the corresponding coefficients from other datasets. We only fitted quadratic models
using the PHE (2017) dataset, but we did see a negative value quadratic (β) coefficient
as expected, due to the saturation effect.
Using the summary statistics from the PHE (2017) fitted models, we were able to
verify the relationship between Poisson and quasi-Poisson standard errors (and thus vari-
ances) in R. Quasi-Poisson standard errors can be calculated by multiplying the corre-
sponding Poisson standard errors by the square root of the dispersion. Thus, for pa-
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rameter estimates θˆ, SEQ(θˆ) =
√
φSEP (θˆ) (Equation 3.9). Knowing this we can also
calculate quasi-Poisson variances from Poisson ones with VarQ(θˆ) = φVarP (θˆ) (Equation
3.8). Our PHE (2017) fitted linear models had comparatively small standard errors asso-
ciated with their coefficients, whilst the PHE (2018) standard errors were larger overall.
This was expected though, and can be easily explained by our choice to fit a joint model
to the data, as combining multiple fitted coefficients for the 4h and 24h slopes and inter-
cepts also meant combining their standard errors. As well as this, there were a greater
number of observed yields available for the 2017 data.
Calculating the variances associated with our fitted models’ coefficients led us to
successfully use the Delta Method to work out the uncertainty associated with a given
dose. We realised that this equation could be rewritten as a quadratic with the yield y
as the subject, but in the end this proved to be of little use. At first, we did consider the
uncertainty on all eight of the Poisson and quasi-Poisson fits for the PHE (2017) dataset,
although ultimately we decided to focus on the quasi-Poisson fits as they have larger
variances (both for each coefficient and overall). We split the uncertainty equation up
into “terms”, the coefficients of each variable’s variance σ2 multiplied by the variance itself
(see Section 4.4.3 for more details) to determine how much each coefficient contributed
to the total uncertainty. From doing this with the quasi-Poisson fits at yields of 1 and 5
foci/cell (Figures D.2 and 4.1 respectively) we can clearly see that introducing a quadratic
(or β) term vastly increases the uncertainty on the dose, potentially to levels where the
uncertainty is so large as to be effectively useless. The total uncertainty is far lower
for linear fits, and thus they are preferable to quadratic ones when fitting dose-response
curves. This new plotting technique thus justifies the existing literature’s preference for
linear fits (and their lack of use of quadratic fits). The factsheet explicitly states that
they do not consider the effects of the sampling time, but, at least with our PHE (2017)
data, it is noticeable that the 24h fits (with their smaller slope coefficients) have greater
uncertainty attached to them than the 1h ones, by roughly two orders of magnitude. This
would need checking with other datasets before any firm conclusions are drawn, though.
We were ultimately able to use reference samples to validate some fitted curves, calcu-
late reference sampling ratios, and use those ratios to adjust our previously fitted models.
Upon calculating yields for our existing models at the two control dose points, 0Gy and
1.5Gy, we discovered that only the two 1.5Gy yields for the 24h fits (linear and quadratic)
were within the required 30% discrepancy interval for curve validation. However, as the
1.5Gy is a more important control dose than 0Gy, we could still technically validate the
two 24h curves. We were then successfully able to calculate the reference sampling ratio
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and adjust the dose equations accordingly.
However, understandably, the work done for this thesis was not without some issues,
especially when it came to introducing the second dataset (PHE (2018)). This dataset,
unlike our original one, contained data that was scored by two different scientists, and we
performed a two sample t test that showed a significant difference between their scored
counts. This presented an issue as we then had to normalise and correct the data. As
well as this, we had to ensure that the data points we chose to use as reference samples
were scored by the same person to avoid scorer issues affecting the calculations. Our
individual corrected data points cannot be directly compared to the integer counts from
the other dataset as they are not actually scored cells. The correction part of this process
(detailed in Section 5.2.2) was followed by aggregating the data to give 22 data points to
fit models with. We faced some issues with fitting the models, as the twelve 0Gy data
points had the same corrected value, but did end up successfully fitting joint models for
this data which did prove to be useful. If we were to try and fit this data using GLMs
again it may be worth trying to use the full corrected data without aggregation, to see
if it would be possible to do so, then compare any dose-response curves fitted to those
fitted using the aggregated data.
It is notable that our PHE (2017) linear calibration curves could not be fully validated
using the method as written in the factsheet due to none of the 0Gy yields being within
the 30% discrepancy interval. The factsheet requires a discrepancy of less than 30% for
both control points in order for a curve to be validated. However, we were able to validate
two of the curves (24h linear and quadratic) on a technicality, by arguing that the 1.5Gy
control point is of greater importance. (We did also construct alternative curves instead
if needed.) Some of our issues with the reference samples may have been due to using
readings from the PHE (2018) dataset as control samples. These may not have been
scored by the same person and in identical conditions, and there were noted issues with
multiple scorers in this dataset.
Although we were able to draw interesting and useful conclusions from our Delta
Method/uncertainty graphs for the PHE (2017) dataset, it should be noted that this
particular type of graph is a new technique that requires testing further to see if it
is of use in general for this method, rather than just for this dataset. Theoretically
it is applicable to other datasets with dose-response calibration curves, but there is a
significant difference between theory and practice.
We also had a slight issue with the formulas listed on the factsheet. PHE suggested
estimating the standard error on the yield, σy, with the equation σy =
√
y
n
in the Poisson
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case.
From a practical perspective, there are some obvious issues with the sample timepoints
used in this thesis. A 1h timepoint (as seen in the PHE (2017) dataset) may be useful
statistically, but in a real life situation it is very unlikely that a blood sample would be
successfully taken an hour after a suspected radiation exposure. The factsheet suggests
using 4h and 24h as default timepoints, but flags up another potential issue: that the
calibration curves and estimates calculated will only work well for samples taken near
these timepoints. If this is not the case, further calibration curves should be constructed
if possible, or a different assay should be used.
Radiation biodosimetry as a research area is primarily concerned with working out
how much radiation a person has been exposed to as accurately as possible. Methods that
can process a large number of samples relatively quickly are preferable for potential triage
situations, although many real life radiation exposures affect smaller numbers of people.
Within that context, our aim was to see if proposed standard procedure by PHE, a UK
Government agency of the Department of Health and Social Care, would be feasible for
dose estimation and thus how useful the factsheet detailing it is. Overall we discovered
that yes, the methods did work, and the factsheet is of use to people wishing to analyse
γ-H2AX assay data. The standard error equation stated only works for Poisson fits, and
applying the 30% discrepancy interval validation benchmark to intercept coefficients as
well as slope and quadratic ones can be problematic. Despite these (relatively minor)
issues, the factsheet is a good framework overall for analysing foci data. Analysing this
factsheet and testing its methods also led us to learn that linear fits are preferable to
quadratic ones for dose-response curves, and that quasi-Poisson models are of more use
than Poisson ones for fitting dose-response models. This work also helped construct
a unified statistical methodology for calibration curve estimation, dose estimation, and
uncertainty quantification with the γ-H2AX assay, and this fed into a published paper
[10].
If we were to potentially extend this project, applying the techniques to more datasets
for verifications would be useful, especially to verify the effectiveness of the new uncer-
tainty graphs that we created. We could also look more at various validation criteria for
dose-response curves using reference samples, including applying different ones to each
coefficient, to see if 30% is truly the best option possible.
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Appendix A
Dataset Summaries
A.1 First Dataset - PHE (2017)
Figure A.1: A screenshot of part of our first dataset, showing the raw data.
63
A.2 Second Dataset - PHE (2018)
Figure A.2: A screenshot of part of our second dataset, showing the raw data being
inputted. The scenario shown in part here is actually 0Gy data, due to the 0% stated
exposure.
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Figure A.3: A screenshot of part of our second dataset. The yellow column shows the
percentage of the sample that was exposed to the stated dose. In this case this is 0, so
we actually have 0Gy data here. The “Result” column gives the scored foci count per
cell. The right hand column shows initial normalisation by PHE scientists.
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Appendix B
List of Partial Derivatives
B.1 Dose Equations
1. D = (y−A)
α
(linear, not including reference sampling ratio)
2. D =
−α+
√
α2+4β(y−A)
2β
(quadratic, not including reference sampling ratio)
3. D = (y−A)
α
r (linear, including reference sampling ratio)
4. D =
−α+
√
α2+4β(y−A)
2β
r (quadratic, including reference sampling ratio)
B.2 Not Including Reference Sampling Ratio
B.2.1 Linear
Dose equation:
DL =
(y − A)
α
Partial derivatives:
∂DL
∂A
=
−1
α
∂DL
∂y
=
1
α
∂DL
∂α
=
A− y
α2
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B.2.2 Quadratic
Dose equation:
DQ =
−α +√α2 + 4β (y − A)
2β
Partial derivatives:
∂DQ
∂A
=
1√
α2 + 4β(y − A)
∂DQ
∂y
=
−1√
α2 + 4β(y − A)
∂DQ
∂α
=
1
2β
(
α√
α2 + 4β(y − A) − 1
)
∂DQ
∂β
=
1
β
(
y − A√
α2 + 4β(y − A) +
α
2β
−
√
α2 + 4β(y − A)
2β
)
B.3 Including Reference Sampling Ratio
B.3.1 Linear
Dose equation:
DLr =
(y − A)
α
r
Partial derivatives:
∂DLr
∂A
=
−r
α
∂DLr
∂y
=
r
α
∂DLr
∂α
=
r(A− y)
α2
∂DLr
∂r
=
y − A
α
= DL
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B.3.2 Quadratic
Dose equation:
DQr =
−α +√α2 + 4β (y − A)
2β
r
Partial derivatives:
∂DQr
∂A
=
r√
α2 + 4β(y − A)
∂DQr
∂y
=
−r√
α2 + 4β(y − A)
∂DQr
∂α
=
r
2β
(
α√
α2 + 4β(y − A) − 1
)
∂DQr
∂β
=
r
β
(
y − A√
α2 + 4β(y − A) +
α
2β
−
√
α2 + 4β(y − A)
2β
)
∂DQr
∂r
=
−α +√α2 + 4β(y − A)
2β
= DQ
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Appendix C
Code
C.1 General Case
#linear y reformulation
s2D.liy<- function(y,fit,n,count){
A1<- fit$coefficients[[1]]
a1<- fit$coefficients[[2]]
d1li<-summary(fit)$dispersion
s2A1<- vcov(fit)[1,1]
s2a1<- vcov(fit)[2,2]
s2y1<- d1li*y/n
k1<- s2a1/a1^4
k2<- (-2*A1*s2a1)/a1^4
k3<- a1^-2*(s2A1+s2y1+A1^2*s2a1/a1^2)
k=c(k1,-k2,k3)
names(k)=c("y^2","y","constant")
barplot(k, xlab="Coefficients, listed by order of y",ylab="Value",
main="Linear,y")
sigma2D1q<- k1*y^2+k2*y+k3
print(k)
return(sigma2D1q)
}
#linear
s2D.li<- function(y,fit,n,count){
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A1<- fit$coefficients[[1]]
a1<- fit$coefficients[[2]]
d1li<-summary(fit)$dispersion
s2A1<- vcov(fit)[1,1]
s2a1<- vcov(fit)[2,2]
s2y1<- d1li*y/n
q1<-s2A1/a1^2
q2<-s2y1/a1^2
q3<-(A1-y)^2*s2a1*a1^-4
q=c(q1,q2,q3)
names(q)=c("A","y","alpha")
barplot(q, xlab=expression(paste("Coefficients of ", sigma^2)),ylab="Value",
main="Linear")
sigma2D1<- q1+q2+q3
print(q)
return(sigma2D1)
}
#quadratic
s2D.qu<- function(y,fit,n,count){
A3<- fit$coefficients[[1]]
a3<- fit$coefficients[[2]]
b3<- fit$coefficients[[3]]
d1qu<-summary(fit)$dispersion
s2A3<- vcov(fit)[1,1]
s2a3<- vcov(fit)[2,2]
s2b3<- vcov(fit)[3,3]
s2y3<- d1qu*y/n
z3<- a3^2+4*b3*(y-A3)
m1<- s2A3/z3
m2<- s2y3/z3
m3<- (-1+a3/z3^0.5)^2*s2a3*0.25*b3^-2
m4<- ((y-A3)^2/z3+a3*(y-A3)*b3^-1*z3^-0.5+(y-A3)/b3+a3*z3^0.5*b3^-2*0.5+
a3^2*b3^-2*0.25+z3*b3^-2*0.25)*s2b3*b3^-2
m=c(m1,m2,m3,m4)
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names(m)=c("A","y","alpha","beta")
barplot(m, xlab=expression(paste("Coefficients of ", sigma^2)),ylab="Value",
main="Quadratic")
sigma2D3q<- m1+m2+m3+m4
print(m)
return(sigma2D3q)
}
C.2 Supplementary Code For Section 4.5.2
#values for a yield of 5 foci/cell (with code)
n=500
Y=5
#linear, 1h
s2D1qdx<- function(y){
A1<- fit1q.li$coefficients[[1]]
a1<- fit1q.li$coefficients[[2]]
d1li<-summary(fit1q.li)$dispersion
s2A1<- c1q.li$cov[1,1]
s2a1<- c1q.li$cov[2,2]
s2y1<- d1li*y/n
q1<-s2A1/a1^2
q2<-s2y1/a1^2
q3<-(A1-y)^2*s2a1*a1^-4
q=c(q1,q2,q3)
names(q)=c("A","y","alpha")
barplot(q, xlab=expression(paste("Coefficients of ", sigma^2)),ylab="Value",
main="Quasi-poisson, linear, 1h")
sigma2D1<- q1+q2+q3
print(q)
return(sigma2D1)
}
#linear, 24h
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s2D2qdx<- function(y){
A2<- fit24q.li$coefficients[[1]]
a2<- fit24q.li$coefficients[[2]]
d24li<-summary(fit24q.li)$dispersion
s2A2<- c24q.li$cov[1,1]
s2a2<- c24q.li$cov[2,2]
s2y2<- d24li*y/n
q1<-s2A2/a2^2
q2<-s2y2/a2^2
q3<-(A2-y)^2*s2a2*a2^-4
q=c(q1,q2,q3)
names(q)=c("A","y","alpha")
barplot(q, xlab=expression(paste("Coefficients of ", sigma^2)),ylab="Value",
main="Quasi-poisson, linear, 24h")
sigma2D2<- q1+q2+q3
print(q)
return(sigma2D2)
}
#quadratic, 1h
s2D3qd<- function(y){
A3<- fit1q.qu$coefficients[[1]]
a3<- fit1q.qu$coefficients[[2]]
b3<- fit1q.qu$coefficients[[3]]
d1qu<-summary(fit1q.qu)$dispersion
s2A3<- c1q.qu$cov[1,1]
s2a3<- c1q.qu$cov[2,2]
s2b3<- c1q.qu$cov[3,3]
s2y3<- d1qu*y/n
z3<- a3^2+4*b3*(y-A3)
m1<- s2A3/z3
m2<- s2y3/z3
m3<- (-1+a3/z3^0.5)^2*s2a3*0.25*b3^-2
m4<- ((y-A3)^2/z3+a3*(y-A3)*b3^-1*z3^-0.5+(y-A3)/b3+a3*z3^0.5*b3^-2*0.5+
a3^2*b3^-2*0.25+z3*b3^-2*0.25)*s2b3*b3^-2
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m=c(m1,m2,m3,m4)
names(m)=c("A","y","alpha","beta")
barplot(m, xlab=expression(paste("Coefficients of ", sigma^2)),ylab="Value",
main="Quasi-poisson, quadratic, 1h")
sigma2D3q<- m1+m2+m3+m4
print(m)
return(sigma2D3q)
}
#quadratic, 24h
s2D4qd<- function(y){
A4<- fit24q.qu$coefficients[[1]]
a4<- fit24q.qu$coefficients[[2]]
b4<- fit24q.qu$coefficients[[3]]
d24qu<-summary(fit24q.qu)$dispersion
s2A4<- c24q.qu$cov[1,1]
s2a4<- c24q.qu$cov[2,2]
s2b4<- c24q.qu$cov[3,3]
s2y4<- d24qu*y/n
z4<- a4^2+4*b4*(y-A4)
m1<- s2A4/z4
m2<- s2y4/z4
m3<- (-1+a4/z4^0.5)^2*s2a4*0.25*b4^-2
m4<- ((y-A4)^2/z4+a4*(y-A4)*b4^-1*z4^-0.5+(y-A4)/b4+a4*z4^0.5*b4^-2*0.5+
a4^2*b4^-2*0.25+z4*b4^-2*0.25)*s2b4*b4^-2
m=c(m1,m2,m3,m4)
names(m)=c("A","y","alpha","beta")
barplot(m, xlab=expression(paste("Coefficients of ", sigma^2)),ylab="Value",
main="Quasi-poisson, quadratic, 24h")
sigma2D4q<- m1+m2+m3+m4
print(m)
return(sigma2D4q)
}
par(mfrow=c(2,2))
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Appendix D
Plots
All dose estimates in this appendix are given to four decimal places.
D.1 Yield of 5 foci/cell, Continued From Section 4.5.2
Fit type Time Dose Estimate (Gy)
Linear
1h 0.3877
24h 2.4884
Quadratic
1h 0.3477
24h 2.3675
Table D.1: Dose estimates for a yield of 5 foci/cell in Gray, to four decimal places.
D.2 Yield of 1 foci/cell
Fit type Time Dose Estimate (Gy)
Linear
1h 0.0692
24h 0.4236
Quadratic
1h 0.0581
24h 0.3834
Table D.2: Dose estimates for a yield of 1 foci/cell in Gray, to four decimal places.
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Figure D.1: A series of twelve plots showing the contribution to the overall uncertainty
for each “term” in a given scenario with a yield of 1 foci/cell.
Linear:
D =
1− 0.130838
12.558857
= 0.0692Gy
Quadratic:
D =
−15.507491 +√15.5074912 + 4×−4.169313 (1− 0.112397)
2×−4.169313 =
−15.507491 +√225.6795
−8.338626
D = 0.0581Gy
24h:
Linear:
D =
1− 0.179394
1.937251
= 0.4236Gy
Quadratic:
D =
−2.275551 +√2.2755512 + 4×−0.094352 (1− 0.141415)
2×−0.094352 =
−2.275551 +√4.854096
−0.188704
D = 0.3834Gy
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Figure D.2: A series of four plots showing the contribution to the overall uncertainty for
each “term” in a given scenario, accompanying the code given in Appendix C for a yield
of 1 foci/cell. This figure is the 1 foci/cell equivalent of Figure 4.1
76
y^2 y constant
Poisson, linear, 1h, y
Coefficients, listed by order of y
Va
lu
e
0.
0e
+0
0
6.
0e
−0
6
1.
2e
−0
5
A y alpha
Poisson, linear, 1h
Coefficients of σ2
Va
lu
e
0.
0e
+0
0
6.
0e
−0
6
1.
2e
−0
5
y^2 y constant
Poisson, linear, 24h, y
Coefficients, listed by order of y
Va
lu
e
0e
+0
0
2e
−0
4
4e
−0
4
A y alpha
Poisson, linear, 24h
Coefficients of σ2
Va
lu
e
0e
+0
0
2e
−0
4
4e
−0
4
A y alpha beta
Poisson, quadratic, 1h
Coefficients of σ2
Va
lu
e
0.
00
00
0.
00
15
0.
00
30
A y alpha beta
Poisson, quadratic, 24h
Coefficients of σ2
Va
lu
e
0.
0
0.
2
0.
4
0.
6
0.
8
y^2 y constant
Quasi−poisson, linear, 1h, y
Coefficients, listed by order of y
Va
lu
e
0e
+0
0
3e
−0
4
6e
−0
4
A y alpha
Quasi−poisson, linear, 1h
Coefficients of σ2
Va
lu
e
0e
+0
0
3e
−0
4
6e
−0
4
y^2 y constant
Quasi−poisson, linear, 24h, y
Coefficients, listed by order of y
Va
lu
e
0.
00
0
0.
01
0
0.
02
0
0.
03
0
A y alpha
Quasi−poisson, linear, 24h
Coefficients of σ2
Va
lu
e
0.
00
0
0.
01
0
0.
02
0
0.
03
0
A y alpha beta
Quasi−poisson, quadratic, 1h
Coefficients of σ2
Va
lu
e
0.
00
0.
05
0.
10
0.
15
A y alpha beta
Quasi−poisson, quadratic, 24h
Coefficients of σ2
Va
lu
e
0
10
20
30
40
50
Figure D.3: A series of twelve plots showing the contribution to the overall uncertainty
for each “term” in a given scenario with a yield of 1 foci/cell.
77
78
Bibliography
[1] Jochen Einbeck. Radiation dosimetry through statistical analysis of biomarkers. Pre-
sentation for Undergraduate Colloquium. Durham: Durham University.
[2] M Sun et al. Doses in Radiation Accidents Investigated by Chromosomal Aberration
Analysis XXV. Review of cases investigated, 2006-2015. Public Health England,
2016.
[3] Jayne Moquet et al. “The second gamma-H2AX assay inter-comparison exercise
carried out in the framework of the European biodosimetry network (RENEB)”.
In: International Journal of Radiation Biology 93.1 (2017), pp. 58–64.
[4] M Sz luin´ska, A A Edwards, and D C Lloyd. Statistical Methods for Biological
Dosimetry. type. Health Protection Agency, Centre for Radiation, Chemical and
Environmental Hazards, Radiation Protection Division, 2005.
[5] International Atomic Energy Agency. Cytogenetic Dosimetry: Applications in Pre-
paredness for and Response to Radiation Emergencies. Austria: IAEA, 2011, pp. 1–
100.
[6] Jochen Einbeck et al. “On the use of random effect models for radiation bio-
dosimetry”. In: Extended Abstracts Fall 2015. Vol. 8. Trends in Mathematics. Basel:
Birkha¨user, Cham, pp. 89–94.
[7] Kai Rothkamm et al. “Manual versus automated γ-H2AX foci analysis across five
European laboratories: Can this assay be used for rapid biodosimetry in a large
scale radiation accident?” In: Mutation Research 756 (2013), pp. 170–173.
[8] Bulletin. Newsletter. Realising the European Network of Biodosimetry, 2015.
[9] Elizabeth Ainsbury. Dose and uncertainty estimation with the gamma-H2AX assay.
Unpublished Factsheet. Public Health England, 2016.
[10] Jochen Einbeck et al. “A statistical framework for radiation dose estimation with
uncertainty quantification from the γ-H2AX assay”. In: PLoS One 13.11 (2018).
79
[11] Aida Muslimovic, Pegah Johansson, and Ola Hammarsten. “Measurement of H2AX
Phosphorylation as a Marker of Ionizing Radiation Induced Cell Damage”. In: Cur-
rent Topics in Ionizing Radiation Research. 2012. isbn: 978-953-51-0196-3.
[12] Dane Avondoglio et al. “High throughput evaluation of gamma-H2AX”. In: Radi-
ation Oncology 4.31 (2009).
[13] Emmy P. Rogakou et al. “DNA Double-stranded Breaks Induce Histone H2AX
Phosphorylation on Serine 139”. In: The Journal of Biological Chemistry 273.10
(1998), pp. 5858–5868.
[14] Jochen Einbeck. The H2AX-histone as a radiation biomarker - modelling and dose
estimation. Presentation for Mini Workshop on Protein Structure Prediction and
Modelling. Durham University.
[15] Kai Rothkamm and Simon Horn. “γ-H2AX as protein biomarker for radiation ex-
posure”. In: Annali dell’Istituto Superiore Di Sanita` 45.3 (9), pp. 265–271.
[16] Jayne Moquet, Stephen Barnard, and Kai Rothkamm. “Gamma-H2AX biodosime-
try for use in large scale radiation incidents: comparison of a rapid ’96 well lyse/fix’
protocol with a routine method”. In: PeerJ (2014). Ed. by Sren Bentzen.
[17] Jochen Einbeck. Radiation dose estimation through the gamma-H2AX protein. Pre-
sentation for BSI Research Showcase. Durham: Durham University.
[18] K. Rothkamm et al. “Laboratory Intercomparison on the γ-H2AX Foci Assay”. In:
Radiation Research 180.2 (2013), pp. 149–155.
[19] Norman L. Johnson, Adrienne W. Kemp, and Samuel Kotz. Univariate Discrete
Distributions. 3rd. Wiley Series in Probability and Statistics. Hoboken, New Jersey:
John Wiley and Sons, Inc, 2005. Chap. 4. isbn: 978-0-471-27246-5.
[20] A. Colin Cameron and Pravin K. Trivedi. Regression Analysis of Count Data.
Econometric Society Monographs. Cambridge: Cambridge University Press, 1998.
Chap. 3, pp. 59–85. isbn: 0-521-63567-5.
[21] A. Hilali et al. “An Appraisal of the Value of the Contaminated Poisson Method
to Estimate the Dose Inhomogeneity in Simulated Partial-Body Exposure”. In:
Radiation Research 128.1 (1991), pp. 108–111.
[22] Simon Horn, Stephen Barnard, and Kai Rothkamm. “Gamma-H2AX-Based Dose
Estimation for Whole and Partial Body Radiation Exposure”. In: PLoS One 6.9
(2011).
80
[23] Mara Oliveira et al. “Zero-inflated regression models for radiation-induced chromo-
some aberration data: A comparative study”. In: Biometrical Journal 58.2 (2015),
pp. 259–279.
[24] Kai Rothkamm et al. “DNA Damage Foci: Meaning and Significance”. In: Envi-
ronmental and Molecular Mutagenesis 56.6 (2015), pp. 491–504.
[25] Jay M. Ver Hoef and Peter L. Boveng. “Quasi-Poisson vs. Negative Binomial Re-
gression: How Should We Model Overdispersed Count Data?” In: Ecology 88.11
(2007), 27662772.
[26] Ludwig Fahrmeir and Gerhard Tutz. Multivariate Statistical Modelling Based on
Generalized Linear Models. 2nd. Springer Series in Statistics. Springer-Verlag, 2001,
pp. 55–60. isbn: 0-387-95187-3.
[27] Adam Errington. “Investigating the Role of Zero-Inflated Models in Relation to
Dose Estimation”. MSc. University of Durham, 2017.
[28] Elizabeth Ainsbury et al. “Uncertainty of fast biological radiation dose assessment
for emergency response scenarios”. In: International Journal of Radiation Biology
93.1 (2017), pp. 127–135.
[29] Yuqi Gao. “γ-H2AX-based Dose Estimation via Standard Methodology in Dicentric
Assay”. Master of Science Dissertation. University of Durham, 2017.
[30] Joint Committee For Guides In Metrology. Evaluation of measurement data Guide
to the expression of uncertainty in measurement. 1st. 100.
81
